Waters (WAT) 10-Q 3 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Oct. 01, 2022	Oct. 28, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Interactive Data Current	Yes
Entity Central Index Key	0001000697
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Oct. 01, 2022
Entity Registrant Name	Waters Corporation
Entity File Number	01-14010
Entity Tax Identification Number	13-3668640
Entity Incorporation, State or Country Code	DE
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	34 Maple Street
Entity Address, City or Town	Milford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01757
City Area Code	508
Local Phone Number	478-2000
Trading Symbol	WAT
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		59,407,575

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 443,637	$ 501,234
Investments	876	68,051
Accounts receivable, net	600,924	612,648
Inventories	442,236	356,095
Other current assets	87,912	90,914
Total current assets	1,575,585	1,628,942
Property, plant and equipment, net	547,386	547,913
Intangible assets, net	213,429	242,401
Goodwill	420,257	437,865
Operating lease assets	86,285	84,734
Other assets	227,111	153,077
Total assets	3,070,053	3,094,932
Current liabilities:
Notes payable and debt	50,000	0
Accounts payable	96,567	96,799
Accrued employee compensation	64,554	101,192
Deferred revenue and customer advances	248,884	227,561
Current operating lease liabilities	24,231	27,906
Accrued income taxes	116,819	61,278
Accrued warranty	10,661	10,718
Other current liabilities	120,254	155,054
Total current liabilities	731,970	680,508
Long-term liabilities:
Long-term debt	1,494,626	1,513,870
Long-term portion of retirement benefits	48,798	64,027
Long-term income tax liabilities	248,111	319,547
Long-term operating lease liabilities	61,470	59,623
Other long-term liabilities	99,842	89,803
Total long-term liabilities	1,952,847	2,046,870
Total liabilities	2,684,817	2,727,378
Commitments and contingencies (Notes 6, 7, 8 and 12)
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued at October 1, 2022 and December 31, 2021	0	0
Common stock, par value $0.01 per share, 400,000 shares authorized, 162,379 and 162,084 shares issued, 59,534 and 60,728 shares outstanding at October 1, 2022 and December 31, 2021, respectively	1,624	1,621
Additional paid-in capital	2,181,558	2,114,880
Retained earnings	8,281,525	7,800,832
Treasury stock, at cost, 102,845 and 101,356 shares at October 1, 2022 and December 31, 2021, respectively	(9,915,081)	(9,437,914)
Accumulated other comprehensive loss	(164,390)	(111,865)
Total stockholders' equity	385,236	367,554
Total liabilities and stockholders' equity	$ 3,070,053	$ 3,094,932

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 01, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	162,379,000	162,084,000
Common stock, shares outstanding	59,534,000	60,728,000
Treasury stock, shares	102,845,000	101,356,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Revenues:
Total net sales	$ 708,555	$ 659,233	$ 2,113,446	$ 1,949,425
Costs and operating expenses:
Selling and administrative expenses	164,417	152,545	483,769	453,954
Research and development expenses	43,435	41,986	127,913	125,027
Purchased intangibles amortization	1,592	1,759	4,863	5,408
Acquired in-process research and development			9,797	0
Total costs and operating expenses	516,545	467,418	1,526,334	1,389,918
Operating income	192,010	191,815	587,112	559,507
Other income (expense), net	895	(607)	2,600	18,073
Interest expense	(12,420)	(11,081)	(34,898)	(34,054)
Interest income	2,896	2,548	7,536	10,347
Income before income taxes	183,381	182,675	562,350	553,873
Provision for income taxes	27,383	21,490	81,657	77,269
Net income	$ 155,998	$ 161,185	$ 480,693	$ 476,604
Net income per basic common share	$ 2.61	$ 2.63	$ 7.98	$ 7.72
Weighted-average number of basic common shares	59,801	61,359	60,200	61,771
Net income per diluted common share	$ 2.6	$ 2.6	$ 7.94	$ 7.66
Weighted-average number of diluted common shares and equivalents	60,081	61,888	60,521	62,244
Product [Member]
Revenues:
Total net sales	$ 464,923	$ 419,133	$ 1,385,393	$ 1,242,110
Costs and operating expenses:
Costs and operating expenses	199,918	171,364	593,884	506,985
Service [Member]
Revenues:
Total net sales	243,632	240,100	728,053	707,315
Costs and operating expenses:
Costs and operating expenses	$ 107,183	$ 99,764	$ 306,108	$ 298,544

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 155,998	$ 161,185	$ 480,693	$ 476,604
Other comprehensive (loss) income:
Foreign currency translation	(23,779)	(4,560)	(54,255)	1,256
Unrealized gains on investments before income taxes	0	17	26	2
Income tax expense	0		(6)
Unrealized gainson investments, net of tax	0	17	20	2
Retirement liability adjustment before reclassifications	767	(103)	1,755	691
Amounts reclassified to other income, net	254	248	501	682
Retirement liability adjustment before income taxes	1,021	145	2,256	1,373
Income tax expense	(243)	(37)	(546)	(302)
Retirement liability adjustment, net of tax	778	108	1,710	1,071
Other comprehensive (loss) income	(23,001)	(4,435)	(52,525)	2,329
Comprehensive income	$ 132,997	$ 156,750	$ 428,168	$ 478,933

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Cash flows from operating activities:
Net income	$ 480,693	$ 476,604
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	30,929	21,949
Deferred income taxes	(20,836)	9,219
Depreciation	54,306	52,760
Amortization of intangibles	44,799	45,166
Acquired in-process research and development and other non-cash items	10,003	0
Change in operating assets and liabilities:
(Increase) decrease in accounts receivable	(39,098)	23,472
Increase in inventories	(113,211)	(93,878)
Increase in other current assets	(6,861)	(9,123)
Increase in other assets	(3,881)	(6,116)
Decrease in accounts payable and other current liabilities	(4,952)	(4,768)
Increase in deferred revenue and customer advances	47,060	71,889
Decrease in other liabilities	(65,999)	(57,838)
Net cash provided by operating activities	412,952	529,336
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization	(113,737)	(116,614)
Proceeds from (investments in) equity investments, net	8,903	(867)
Payments for intellectual property licenses	(7,535)	(7,000)
Purchases of investments	(11,407)	(241,230)
Maturities and sales of investments	77,993	117,283
Net cash used in investing activities	(45,783)	(248,428)
Cash flows from financing activities:
Proceeds from debt issuances	165,000	510,000
Payments on debt	(135,000)	(250,000)
Payments of debt issuance costs	0	(8,537)
Proceeds from stock plans	36,136	55,000
Purchases of treasury shares	(477,167)	(492,695)
Proceeds from derivative contracts	12,844	2,325
Net cash used in financing activities	(398,187)	(183,907)
Effect of exchange rate changes on cash and cash equivalents	(26,579)	(8,994)
(Decrease) increase in cash and cash equivalents	(57,597)	88,007
Cash and cash equivalents at beginning of period	501,234	436,695
Cash and cash equivalents at end of period	$ 443,637	$ 524,702

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning balance at Dec. 31, 2020	$ 232,144	$ 1,617	$ 2,029,465	$ 7,107,989	$ (8,788,984)	$ (117,943)
Beginning Balance, shares at Dec. 31, 2020		161,666
Net income	476,604			476,604
Other comprehensive income (loss)	2,329					2,329
Issuance of common stock for Employee Stock Purchase Plan	9,578		9,578
Issuance of common stock for Employee Stock Purchase Plan, shares		40
Issuance of common stock for stock options exercised	46,112	$ 3	46,109
Issuance of common stock for stock options exercised, shares		275
Treasury stock	(492,695)				(492,695)
Stock-based compensation	21,150	$ 1	21,149
Stock-based compensation, shares		94
Ending balance at Oct. 02, 2021	295,222	$ 1,621	2,106,301	7,584,593	(9,281,679)	(115,614)
Ending Balance, shares at Oct. 02, 2021		162,075
Beginning balance at Jul. 03, 2021	268,273	$ 1,620	2,090,052	7,423,408	(9,135,628)	(111,179)
Beginning Balance, shares at Jul. 03, 2021		162,017
Net income	161,185			161,185
Other comprehensive income (loss)	(4,435)					(4,435)
Issuance of common stock for Employee Stock Purchase Plan	2,567		2,567
Issuance of common stock for Employee Stock Purchase Plan, shares		8
Issuance of common stock for stock options exercised	7,397	$ 1	7,396
Issuance of common stock for stock options exercised, shares		45
Treasury stock	(146,051)				(146,051)
Stock-based compensation	6,286	$ 0	6,286
Stock-based compensation, shares		5
Ending balance at Oct. 02, 2021	295,222	$ 1,621	2,106,301	7,584,593	(9,281,679)	(115,614)
Ending Balance, shares at Oct. 02, 2021		162,075
Beginning balance at Dec. 31, 2021	367,554	$ 1,621	2,114,880	7,800,832	(9,437,914)	(111,865)
Beginning Balance, shares at Dec. 31, 2021		162,084
Net income	480,693			480,693
Other comprehensive income (loss)	(52,525)					(52,525)
Issuance of common stock for Employee Stock Purchase Plan	8,374		8,374
Issuance of common stock for Employee Stock Purchase Plan, shares		28
Issuance of common stock for stock options exercised	28,123	$ 2	28,121
Issuance of common stock for stock options exercised, shares		167
Treasury stock	(477,167)				(477,167)
Stock-based compensation	30,184	$ 1	30,183
Stock-based compensation, shares		100
Ending balance at Oct. 01, 2022	385,236	$ 1,624	2,181,558	8,281,525	(9,915,081)	(164,390)
Ending Balance, shares at Oct. 01, 2022		162,379
Beginning balance at Jul. 02, 2022	392,124	$ 1,623	2,166,221	8,125,527	(9,759,858)	(141,389)
Beginning Balance, shares at Jul. 02, 2022		162,348
Net income	155,998			155,998
Other comprehensive income (loss)	(23,001)					(23,001)
Issuance of common stock for Employee Stock Purchase Plan	2,488		2,488
Issuance of common stock for Employee Stock Purchase Plan, shares		9
Issuance of common stock for stock options exercised	2,506		2,506
Issuance of common stock for stock options exercised, shares		17
Treasury stock	(155,223)				(155,223)
Stock-based compensation	10,344	$ 1	10,343
Stock-based compensation, shares		5
Ending balance at Oct. 01, 2022	$ 385,236	$ 1,624	$ 2,181,558	$ 8,281,525	$ (9,915,081)	$ (164,390)
Ending Balance, shares at Oct. 01, 2022		162,379

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1 Basis of Presentation and Summary of Significant Accounting P olicies Waters Corporation (the “Company,” “we,” “our,” or “us”) is a specialty measurement company that operates with a fundamental underlying purpose to advance the science that enables our customers to enhance human health and well-being. The Company has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC TM (“LC-MS”) LC-MS TM The Company’s interim fiscal quarter typically ends on the thirteenth Saturday of each quarter. Since the Company’s fiscal year end is December 31, the first and fourth fiscal quarters may have more or less than thirteen complete weeks. The Company’s third fiscal quarters for 2022 and 2021 ended on October 1, 2022 and October 2, 2021, respectively. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the instructions to the Quarterly Report on Form 10-Q The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities at the dates of the financial statements. Actual amounts may differ from these estimates under different assumptions or conditions. It is management’s opinion that the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K Risks and Uncertainties The Company is subject to risks common to companies in the analytical instrument industry, including, but not limited to, global economic and financial market conditions, fluctuations in foreign currency exchange rates, fluctuations in customer demand, development by its competitors of new technological innovations, costs of developing new technologies, levels of debt and debt service requirements, risk of disruption, dependence on key personnel, protection and litigation of proprietary technology, shifts in taxable income between tax jurisdictions and compliance with regulations of the U.S. Food and Drug Administration and similar foreign regulatory authorities and agencies. Both the Company’s domestic and international operations have been and continue to be affected by the ongoing global COVID-19 COVID-19 Through the date of the issuance of these financial statements, the Company’s consolidated financial position, results of operations and cash flows have not been materially impacted and, thus, the Company concluded that no interim goodwill or long-lived asset impairment analyses were required. Further, there have been no violations of debt covenants. Any prolonged material disruption to the Company’s employees, suppliers, manufacturing, or customers could result in a material impact to its consolidated financial position, results of operations or cash flows in the future. Translation of Foreign Currencies The functional currency of each of the Company’s foreign operating subsidiaries is the local currency of its country of domicile, except for the Company’s subsidiaries in Hong Kong, Singapore and the Cayman Islands, where the underlying transactional cash flows are denominated in currencies other than the respective local currency of domicile. The functional currency of the Hong Kong, Singapore and Cayman Islands subsidiaries is the U.S. dollar, based on the respective entity’s cash flows. For the Company’s foreign operations, assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the balance sheet date, while revenues and expenses are translated at average exchange rates prevailing during the respective period. Any resulting translation gains or losses are included in accumulated other comprehensive loss in the consolidated balance sheets. Cash, Cash Equivalents and Investments Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of October 1, 2022 and December 31, 2021, $409 million out of $445 million and $440 million out of $569 million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries. In addition, $270 million out of $445 million and $298 million out of $569 million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at October 1, 2022 and December 31, 2021, respectively. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company has very limited use of rebates and other cash considerations payable to customers and, as a result, the transaction price determination does not have any material variable consideration. The Company does not consider there to be significant concentrations of credit risk with respect to trade receivables due to the short-term nature of the balances, the Company having a large and diverse customer base, and the Company having a strong historical experience of collecting receivables with minimal defaults. As a result, credit risk is considered low across territories and trade receivables are considered to be a single class of financial asset. The allowance for credit losses is based on a number of factors and is calculated by applying a historical loss rate to trade receivable aging balances to estimate a general reserve balance along with an additional adjustment for any specific receivables with known or anticipated issues affecting the likelihood of recovery. Past due balances with a probability of default based on historical data as well as relevant available forward-looking information are included in the specific adjustment. The historical loss rate is reviewed on at least an annual basis and the allowance for credit losses is reviewed quarterly for any required adjustments. The Company does not have any off-balance Trade receivables related to instrument sales are collateralized by the instrument that is sold. If there is a risk of default related to a receivable that is collateralized, then the fair value of the collateral is calculated and adjusted for the cost to re-possess, re-sell The following is a summary of the activity of the Company’s allowance for credit losses for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Additions Deductions Balance at End Allowance for Credit Losses October 1, 2022 $ 13,228 $ 4,980 $ (4,973 ) $ 13,235 October 2, 2021 $ 14,381 $ 3,388 $ (4,107 ) $ 13,662 Other Investments During the nine months ended October 1, 2022, the Company sold equity investments for $10 million in cash and recorded gains on the sales of approximately $7 million in other income, net on the statement of operations. The Company also incurred $6 million in losses on equity investments recorded within other income, net on the statement of operations. During the nine months ended October 2, 2021, the Company recorded an unrealized gain on an equity security still held at the reporting date of approximately $10 million within other income, net on the statement of operations. This unrealized gain was recorded as an upward price adjustment to the carrying value of the investment due to an observable price change of a similar security. Fair Value Measurements In accordance with the accounting standards for fair value measurements and disclosures, certain of the Company’s assets and liabilities are measured at fair value on a recurring basis as of October 1, 2022 and December 31, 2021. Fair values determined by Level 1 inputs utilize observable data, such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the reporting entity to develop its own assumptions. The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at October 1, 2022 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: Time deposits 876 — 876 — Waters 401(k) Restoration Plan assets 24,099 24,099 — — Foreign currency exchange contracts 278 — 278 — Interest rate cross-currency swap agreements 62,223 — 62,223 — Total $ 87,476 $ 24,099 $ 63,377 $ — Liabilities: Contingent consideration $ 1,469 $ — $ — $ 1,469 Foreign currency exchange contracts 63 — 63 — Total $ 1,532 $ — $ 63 $ 1,469 The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2021 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: U.S. Treasury securities $ 13,917 $ — $ 13,917 $ — Corporate debt securities 39,121 — 39,121 — Time deposits 19,030 — 19,030 — Waters 401(k) Restoration Plan assets 38,729 38,729 — — Foreign currency exchange contracts 504 — 504 — Total $ 111,301 $ 38,729 $ 72,572 $ — Liabilities: Contingent consideration $ 1,347 $ — $ — $ 1,347 Foreign currency exchange contracts 195 — 195 — Interest rate cross-currency swap agreements 5,363 — 5,363 — Total $ 6,905 $ — $ 5,558 $ 1,347 Fair Value of 401(k) Restoration Plan Assets The 401(k) Restoration Plan is a nonqualified defined contribution plan and the assets were held in registered mutual funds and have been classified as Level 1. The fair values of the assets in the plan are determined through market and observable sources from daily quoted prices on nationally recognized securities exchanges. Fair Value of Cash Equivalents, Investments, Foreign Currency Exchange Contracts and Interest Rate Cross-Currency Swap Agreements The fair values of the Company’s cash equivalents, investments, foreign currency exchange contracts and interest rate cross-currency swap agreements are determined through market and observable sources and have been classified as Level 2. These assets and liabilities have been initially valued at the transaction price and subsequently valued, typically utilizing third-party pricing services. The pricing services use many inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, current spot rates and other industry and economic events. The Company validates the prices provided by third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. Fair Value of Contingent Consideration The fair value of the Company’s liability for contingent consideration relates to earnout payments in connection with the December 2020 acquisition of Integrated Software Solutions (“ISS”) and is determined using a probability-weighted discounted cash flow model, which uses significant unobservable inputs, and has been classified as Level 3. Subsequent changes in the fair value of the contingent consideration liability are recorded in the results of operations. The fair value of the contingent consideration liability associated with future earnout payments is based on several factors, including the achievement of certain revenue and customer account milestones over the two years after the acquisition date and a discount rate that reflects both the likelihood of achieving the estimated future results and the Company’s creditworthiness. A change in any of these unobservable inputs can significantly change the fair value of the contingent consideration. The fair value of future contingent consideration payments related to the December 2020 acquisition of ISS was estimated to be $1 million at both October 1, 2022 and December 31, 2021. Fair Value of Other Financial Instruments The Company’s accounts receivable and accounts payable are recorded at cost, which approximates fair value due to their short-term nature. The carrying value of the Company’s variable interest rate debt approximates fair value due to the variable nature of the interest rate. The carrying value of the Company’s fixed interest rate debt was $1.3 billion at both October 1, 2022 and December 31, 2021. The fair value of the Company’s fixed interest rate debt was estimated using discounted cash flow models, based on estimated current rates offered for similar debt under current market conditions for the Company. The fair value of the Company’s fixed interest rate debt was estimated to be $1.1 billion and $1.3 billion at October 1, 2022 and December 31, 2021, respectively, using Level 2 inputs. Derivative Transactions The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates. The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its non-U.S. The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated and Yen-denominated Foreign Currency Exchange Contracts The Company does not specifically enter into any derivatives that hedge foreign-currency-denominated operating assets, liabilities or commitments on its balance sheet, other than a portion of certain third-party accounts receivable and accounts payable, and the Company’s net worldwide intercompany receivables and payables, which are eliminated in consolidation. The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balance to minimize some of the Company’s currency price risk exposure. The foreign currency exchange contracts are not designated for hedge accounting treatment. Principal hedged currencies include the Euro, Japanese yen, British pound, Mexican peso and Brazilian real. Interest Rate Cross-Currency Swap Agreements As of October 1, 2022, the Company had three-year interest rate cross-currency swap derivative agreements with an aggregate notional value of $585 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated and Yen-denominated The Company’s foreign currency exchange contracts and interest rate cross-currency swap agreements included in the consolidated balance sheets are classified as follows (in thousands): October 1, 2022 December 31, 2021 Notional Value Fair Value Notional Value Fair Value Foreign currency exchange contracts: Other current assets $ 42,690 $ 278 $ 55,309 $ 504 Other current liabilities $ 17,000 $ 63 $ 9,000 $ 195 Interest rate cross-currency swap agreements: Other assets $ 585,000 $ 62,223 $ — $ — Other liabilities — — 230,000 5,363 Accumulated other comprehensive income (loss) $ 57,869 $ (15,944 ) The following is a summary of the activity included in the consolidated statements of operations and statements of comprehensive income related to the foreign currency exchange contracts and interest rate cross-currency swap agreements (in thousands): Financial Statement Classification Three Months Ended Nine Months Ended October 1, October 2, October 1, October 2, Foreign currency exchange contracts: Realized (losses) gains on closed contracts Cost of sales $ (3,811 ) $ (774 ) $ (6,603 ) $ 681 Unrealized gains (losses) on open contracts Cost of sales 461 (933 ) (93 ) (2,256 ) Cumulative net pre-tax Cost of sales $ (3,350 ) $ (1,707 ) $ (6,696 ) $ (1,575 ) Interest rate cross-currency swap agreements: Interest earned Interest income $ 2,362 $ 2,305 $ 6,214 $ 9,505 Unrealized gains on open contracts Other comprehensive income $ 31,108 $ 7,762 $ 73,812 $ 24,777 Stockholders’ Equity In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock over a two-year pre-existing program. In Dec e s. Product Warr a s The Compan y accrues estimated product warranty costs at the time of sale, which are included in cost of sales in the consolidated statements of operations. While the Company en g The following is a summary of the activity of the Company’s accrued warranty liability for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Accruals for Settlements Balance at Accrued warranty liability: October 1, 2022 $ 10,718 $ 6,606 $ (6,663 ) $ 10,661 October 2, 2021 $ 10,950 $ 6,537 $ (6,991 ) $ 10,496 Other Items During the nine months ended October 1, 2022, the Company completed an asset acquisition in which the charge detection mass spectrometry technology (“CDMS technology”) assets of Megadalton Solutions, Inc. (“Megadalton”) were acquired for approximately $10 million in total purchase price, of which $5 million was paid at closing and the remaining $4 million will be paid in the future at various dates through 2029. This CDMS technology makes it possible to analyze extremely large proteins and protein complexes used in cell and gene therapies that would otherwise be difficult to analyze with conventional mass spectrometry. Once this technology is further developed, it will extend the capabilities of our mass spectrometry portfolio for a broader set of applications and as such the cost of this technology asset has been accounted for as Acquired In-Process

Revenue Recognition

Revenue Recognition	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	2 Revenue Recognition The Company’s deferred revenue liabilities on the consolidated balance sheets consist of the obligation on instrument service contracts and customer payments received in advance, prior to transfer of control of the instrument. The Company records deferred revenue primarily related to its service contracts, where consideration is billable at the beginning of the service period. The following is a summary of the activity of the Company’s deferred revenue and customer advances for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): October 1, 2022 October 2, 2021 Balance at the beginning of the period $ 273,598 $ 239,759 Recognition of revenue included in balance at beginning of the period (213,527 ) (197,279 ) Revenue deferred during the period, net of revenue recognized 243,853 264,184 Balance at the end of the period $ 303,924 $ 306,664 The Company classified $55 million and $46 million of deferred revenue and customer advances in other long-term liabilities at October 1, 2022 and December 31, 2021, respectively. The amount of deferred revenue and customer advances equals the transaction price allocated to unfulfilled performance obligations for the period presented. Such amounts are expected to be recognized in the future as follows (in thousands): October 1, 2022 Deferred revenue and customer advances expected to be recognized in: One year or less $ 248,884 13 31,632 25 months and beyond 23,408 Total $ 303,924

Marketable Securities

Marketable Securities	9 Months Ended
	Oct. 01, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3 Marketable Securities The Company’s marketable securities within cash equivalents and investments included in the consolidated balance sheets are detailed as follows (in thousands): October 1, 2022 Amortized Unrealized Unrealized Fair Time deposits 876 — — 876 Total $ 876 $ — $ — $ 876 Amounts included in: Investments 876 — — 876 Total $ 876 $ — $ — $ 876 December 31, 2021 Amortized Unrealized Unrealized Fair U.S. Treasury securities $ 13,929 $ — $ (12 ) $ 13,917 Corporate debt securities 39,135 — (14 ) 39,121 Time deposits 19,030 — — 19,030 Total $ 72,094 $ — $ (26 ) $ 72,068 Amounts included in: Cash equivalents $ 4,017 $ — $ — $ 4,017 Investments 68,077 — (26 ) 68,051 Total $ 72,094 $ — $ (26 ) $ 72,068 The estimated fair value of marketable debt securities by maturity date is as follows (in thousands): October 1, 2022 December 31, 2021 Due in one year or less $ 876 $ 71,066 Due after one year through three years — 1,002 Total $ 876 $ 72,068

Inventories

Inventories	9 Months Ended
	Oct. 01, 2022
Inventory Disclosure [Abstract]
Inventories	4 Inventories Inventories are classified as follows (in thousands): October 1, 2022 December 31, 2021 Raw materials $ 186,958 $ 165,240 Work in progress 23,577 19,726 Finished goods 231,701 171,129 Total inventories $ 442,236 $ 356,095

Goodwill and Other Intangibles

Goodwill and Other Intangibles	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	5 Goodwill and Other Intangibles The carrying amount of goodwill was $420 million and $438 million at October 1, 2022 and December 31, 2021, respectively. The effect of foreign currency translation decreased goodwill by $18 million. The Company’s intangible assets included in the consolidated balance sheets are detailed as follows (dollars in thousands): October 1, 2022 December 31, 2021 Gross Accumulated Weighted- Gross Accumulated Weighted- Capitalized software $ 525,196 $ 391,250 5 years $ 575,658 $ 420,862 5 years Purchased intangibles 193,056 160,972 11 years 201,302 163,752 11 years Trademarks 9,680 — — 9,680 — — Licenses 12,739 5,848 6 years 12,635 6,199 7 years Patents and other intangibles 100,255 69,427 8 years 102,353 68,414 8 years Total $ 840,926 $ 627,497 7 years $ 901,628 $ 659,227 7 years The Company capitalized intangible assets in the amounts of $14 million and $18 million in the three months ended October 1, 2022 and October 2, 2021, respectively, and $38 million and $45 million in the nine months ended October 1, 2022 and October 2, 2021, respectively. The gross carrying value of intangible assets and accumulated amortization for intangible assets decreased by $98 million and $76 million, respectively, in the nine months ended October 1, 2022 due to the effects of foreign currency translation. Amortization expense for intangible assets was $15 million for both

Debt

Debt	9 Months Ended
	Oct. 01, 2022
Debt Disclosure [Abstract]
Debt	6 Debt The Company entered into a credit agreement in September 2021 (the “2021 Credit Agreement”) governing the Company’s five-year, $1.8 billion revolving facility (the “2021 Credit Facility”) that expires in September 2026. As of October 1, 2022 and December 31, 2021, the 2021 Credit Facility had a total of $240 million and $210 million outstanding, respectively. The interest rates applicable to the 2021 Credit Agreement are, at the Company’s option, equal to either the alternate base rate (which is a rate per annum equal to the greatest of (1) the prime rate in effect on such day, (2) the Federal Reserve Bank of New York Rate on such day plus 1/2 of 1% per annum and (3) the adjusted LIBO rate on such day (or if such day is not a business day, the immediately preceding business day) for a deposit in U.S. dollars with a maturity of one month plus 1% per annum) or the applicable 1, 3 or 6 month adjusted LIBO rate or EURIBO rate for Euro-denominated loans, in each case, plus an interest rate margin based upon the Company’s leverage ratio, which can range between 0 and 12.5 basis points for alternate base rate loans and between 80 and 112.5 basis points for LIBO rate or EURIBO rate loans. The facility fee on the 2021 Credit Agreement ranges between 7.5 and 25 basis points per annum, based on the leverage ratio, of the amount of the revolving facility commitments and the outstanding term loan. The 2021 Credit Agreement requires that the Company comply with an interest coverage ratio test of not less than 3.50:1 as of the end of any fiscal quarter for any period of four consecutive fiscal quarters and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, the 2021 Credit Agreement includes negative covenants, affirmative covenants, representations and warranties and events of default that are customary for investment grade credit facilities. As of both October 1, 2022 and December 31, 2021, the Company had a total of $1.3 billion of outstanding senior unsecured notes. Interest on the fixed rate senior unsecured notes is payable semi-annually each year. Interest on the floating rate senior unsecured notes is payable quarterly. The Company may prepay all or some of the senior unsecured notes at any time in an amount not less than 10% of the aggregate principal amount outstanding, plus the applicable make-whole amount or prepayment premium for the Series H senior unsecured note. In the event of a change in control of the Company (as defined in the note purchase agreement), the Company may be required to prepay the senior unsecured notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest. These senior unsecured notes require that the Company comply with an interest coverage ratio test of not less for any period of four consecutive fiscal quarters and a leverage ratio test of not more than :1 as of the end of any fiscal quarter. In addition, these senior unsecured notes include customary negative covenants, affirmative covenants, representations and warranties and events of default. The outstanding October 1, 2022 December 31, 2021 Senior unsecured notes - Series I - 3.13%, due May 2023 $ 50,000 $ — Total notes payable and debt, current 50,000 — Senior unsecured notes - Series G - 3.92%, due June 2024 50,000 50,000 Senior unsecured notes - Series H - floating rate*, due June 2024 50,000 50,000 Senior unsecured notes - Series I - 3.13%, due May 2023 — 50,000 Senior unsecured notes - Series K - 3.44%, due May 2026 160,000 160,000 Senior unsecured notes - Series L - 3.31%, due September 2026 200,000 200,000 Senior unsecured notes - Series M - 3.53%, due September 2029 300,000 300,000 Senior unsecured notes - Series N - 1.68%, due March 2026 100,000 100,000 Senior unsecured notes - Series O - 2.25%, due March 2031 400,000 400,000 Credit agreement 240,000 210,000 Unamortized debt issuance costs (5,374 ) (6,130 ) Total long-term debt 1,494,626 1,513,870 Total debt $ 1,544,626 $ 1,513,870 * Series H senior unsecured notes bear interest at a 3-month As of both October 1, 2022 and December 31, 2021, the Company had a total amount available to borrow under the 2021 Credit Agreement of $1.6 billion after outstanding letters of credit. The weighted-average interest rates applicable to the senior unsecured notes and credit agreement borrowings collectively were 3.24% and 2.74% at October 1, 2022 and December 31, 2021, respectively. As of October 1, 2022, the Company was in compliance with all debt covenants. The Company and its foreign subsidiaries also had available short-term lines of credit totaling $111 million and $121 million at October 1, 2022 and December 31, 2021, respectively, for the purpose of short-term borrowing and issuance of commercial guarantees. None of the Company’s foreign subsidiaries had outstanding short-term borrowings as of October 1, 2022 or December 31, 2021. As of October 1, 2022, the Company had entered into three-year interest rate cross-currency swap derivative agreements with an aggregate notional value of $585 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated and Yen-denominated

Income Taxes

Income Taxes	9 Months Ended
	Oct. 01, 2022
Income Tax Disclosure [Abstract]
Income Taxes	7 Income Taxes The four principal jurisdictions in which the Company manufactures are the U.S., Ireland, the U.K. and Singapore, where the statutory tax rates were 21%, 12.5%, 19% and 17%, respectively, as of October 1, 2022. The Company had a contractual tax rate of 0% on qualifying activities in Singapore through March 2021, based upon the achievement of certain contractual milestones. The Company has a new Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% on certain types of income for the period April 1, 2021 through March 31, 2026. The effect of applying the concessionary income tax rates rather than the statutory tax rate to income from qualifying activities in Singapore increased the Company’s net income for the nine months ended October 1, 2022 and October 2, 2021 by $15 million and $13 million, respectively, and increased the Company’s net income per diluted share by $0.25 and $0.20, respectively. The Company’s effective tax rate for the three months ended October 1, 2022 and October 2, 2021 was 14.9% and 11.8%, respectively. The increase in the effective income tax rate can be attributed to the impact of favorable quarter-specific adjustments in the prior year and differences in the proportionate amounts of pre-tax The Company’s effective tax rate for the nine months ended October 1, 2022 and October 2, 2021 was 14.5% and 14.0%, respectively. The differences between the effective tax rates can primarily be attributed to differences in the proportionate amounts of pre-tax The Company accounts for its uncertain tax return positions in accordance with the accounting standards for income taxes, which require financial statement reporting of the expected future tax consequences of uncertain tax reporting positions on the presumption that all concerned tax authorities possess full knowledge of those tax reporting positions, as well as all of the pertinent facts and circumstances, but prohibit any discounting of unrecognized tax benefits associated with those reporting positions for the time value of money. The Company continues to classify interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes. The Company’s gross unrecognized tax benefits, excluding interest and penalties, for both the nine months ended October 1, 2022 and October 2, 2021 were $29 million. With limited exceptions, the Company is no longer subject to tax audit examinations in significant jurisdictions for the years ended on or before December 31, 2016. The Company continuously monitors the lapsing of statutes of limitations on potential tax assessments for related changes in the measurement of unrecognized tax benefits, related net interest and penalties, and deferred tax assets and liabilities. As of October 1, 2022, the Company expects to record reductions in the measurement of its unrecognized tax benefits and related net interest and penalties of $18 million within the next twelve months due to potential tax audit settlements and the lapsing of statutes of limitations on potential tax assessments. The Company does not expect to record any other material reductions in the measurement of its unrecognized tax benefits within the next twelve months.

Other Commitments and Contingen

Other Commitments and Contingencies	9 Months Ended
	Oct. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Other Commitments and Contingencies	8 Other Commitments and Contingencies The Company licenses certain technology and software from third parties in the course of ordinary business. Future minimum license fees payable under existing license agreements as of October 1, 2022 are immaterial for the years ended December 31, 2022 and thereafter. The Company enters into licensing arrangements with third parties that require future milestone or royalty payments contingent upon future events. Upon the achievement of certain milestones in existing agreements, the Company could make additional future payments of up to $2 million. The Company enters into standard indemnification agreements in its ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with patent, copyright or other intellectual property infringement claims by any third party with respect to its current products, as well as claims relating to property damage or personal injury resulting from the performance of services by the Company or its subcontractors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, the Company’s costs to defend lawsuits or settle claims relating to such indemnity agreements have been minimal and management accordingly believes the estimated fair value of these agreements is immaterial.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Oct. 01, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	9 Stock-Based Compensation The Company maintains various stockholder-approved, stock-based compensation plans which allow for the issuance of incentive or non-qualified In May 2020, the Company’s stockholders approved the Company’s 2020 Equity Incentive Plan (“2020 Plan”). As of October 1, 2022, the 2020 Plan had 6.5 million shares available for grant in the form of incentive or non-qualified period. A SAR may be granted alone or in conjunction with an option or other award. Shares of restricted stock, restricted stock units and performance stock units may be issued under the 2020 Plan for such consideration as is determined by the Compensation Committee of the Board of Directors. As of October 1, 2022, the Company had stock options, restricted stock, and restricted and performance stock unit awards outstanding under the 2020 Plan. The Company accounts for stock-based compensation costs in accordance with the accounting standards for stock-based compensation, which require that all share-based payments to employees be recognized in the statements of operations, based on their grant date fair values. The Company recognizes the expense using the straight-line attribution method. The stock-based compensation expense recognized in the consolidated statements of operations is based on awards that ultimately are expected to vest; therefore, the amount of expense has been reduced for estimated forfeitures. Forfeitures are estimated based on historical experience. If actual results differ significantly from these estimates, stock-based compensation expense and the Company’s results of operations could be materially impacted. In addition, if the Company employs different assumptions in the application of these standards, the compensation expense that the Company records in the future periods may differ significantly from what the Company has recorded in the current period. The consolidated statements of operations for the three and nine months ended October 1, 2022 and October 2, 2021 include the following stock-based compensation expense related to stock option awards, restricted stock awards, restricted stock unit awards, performance stock unit awards and the employee stock purchase plan (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Cost of sales $ 478 $ 468 $ 2,420 $ 1,828 Selling and administrative expenses 8,174 4,116 23,607 15,810 Research and development expenses 1,555 1,769 4,902 4,311 Total stock-based compensation $ 10,207 $ 6,353 $ 30,929 $ 21,949 Stock Options In determining the fair value of the stock options, the Company makes a variety of assumptions and estimates, including volatility measures, expected yields and expected stock option lives. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model. The Company uses implied volatility on its publicly-traded options as the basis for its estimate of expected volatility. The Company believes that implied volatility is the most appropriate indicator of expected volatility because it is generally reflective of historical volatility and expectations of how future volatility will differ from historical volatility. The expected life assumption for grants is based on historical experience for the population of non-qualified zero-coupon Nine Months Ended Options Issued and Significant Assumptions Used to Estimate Option Fair Values October 1, 2022 October 2, 2021 Options issued in thousands 138 160 Risk-free interest rate 2.0 % 0.8 % Expected life in years 6 6 Expected volatility 30.7 % 32.4 % Expected dividends — — Nine Months Ended Weighted-Average Exercise Price and Fair Value of Options on the Date of Grant October 1, 2022 October 2, 2021 Exercise price $ 321.12 $ 281.23 Fair value $ 107.95 $ 91.46 The following table summarizes stock option activity for the plans for the nine months ended October 1, 2022 (in thousands, except per share data): Number of Shares Exercise Price per Share Weighted-Average Outstanding at December 31, 2021 691 $ 88.71 to $371.64 $ 202.24 Granted 138 $ 270.49 to $364.59 $ 321.12 Exercised (167 ) $ 88.71 to $279.90 $ 168.37 Canceled (40 ) $ 188.63 to $364.59 $ 253.23 Outstanding at October 1, 2022 622 $ 88.71 to $371.64 $ 234.43 Restricted Stock During the nine months ended October 1, 2022, the Company granted three thousand shares of restricted stock. The weighted-average fair value per share of these awards on the grant date was $364.59. Restricted Stock Units The following table summarizes the unvested restricted stock unit award activity for the nine months ended October 1, 2022 (in thousands, except per share data): Shares Weighted-Average Unvested at December 31, 2021 245 $ 234.97 Granted 98 $ 322.99 Vested (76 ) $ 219.30 Forfeited (23 ) $ 256.22 Unvested at October 1, 2022 244 $ 273.20 Restricted stock units are generally granted annually in February and vest in equal annual installments over a five-year period. Performance Stock Units The Company’s performance stock units are equity compensation awards with a market vesting condition based on the Company’s Total Shareholder Return (“TSR”) relative to the TSR of the components of the S&P Health Care Index. TSR is the change in value of a stock price over time, including the reinvestment of dividends. The vesting schedule ranges from 0% to 200% of the target shares awarded. Beginning with the grants made in 2020, the vesting conditions for performance stock units now include a performance condition based on future sales growth. In determining the fair value of the performance stock units, the Company makes a variety of assumptions and estimates, including volatility measures, expected yields and expected terms. The fair value of each performance stock unit grant was estimated on the date of grant using the Monte Carlo simulation model. The Company uses implied volatility on its publicly-traded options as the basis for its estimate of expected volatility. The Company believes that implied volatility is the most appropriate indicator of expected volatility because it is generally reflective of historical volatility and expectations of how future volatility will differ from historical volatility. The expected life assumption for grants is based on the performance period of the underlying performance stock units. The risk-free interest rate is the yield currently available on U.S. Treasury zero-coupon follows: Nine Months Ended Performance Stock Units Issued and Significant Assumptions Used to Estimate October 1, 2022 October 2, 2021 Performance stock units issued (in thousands) 40 41 Risk-free interest rate 1.6 % 0.2 % Expected life in years 2.9 2.9 Expected volatility 25.4 % 38.7 % Average volatility of peer companies 34.5 % 34.7 % Correlation coefficient 43.0 % 45.8 % Expected dividends — — The following table summarizes the unvested performance stock unit award activity for the nine months ended October 1, 2022 (in thousands, except per share data): Shares Weighted-Average Unvested at December 31, 2021 87 $ 285.73 Granted 40 $ 313.21 Vested (24 ) $ 308.71 Forfeited 8 $ 381.32 Unvested at October 1, 2022 111 $ 297.55

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Earnings Per Share	10 Earnings Per Share Basic and diluted EPS calculations are detailed as follows (in thousands, except per share data): Three Months Ended October 1, 2022 Net Income Weighted- Per Share Net income per basic common share $ 155,998 59,801 $ 2.61 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 280 (0.01 ) Net income per diluted common share $ 155,998 60,081 $ 2.60 Three Months Ended October 2, 2021 Net Income Weighted- Per Share Net income per basic common share $ 161,185 61,359 $ 2.63 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 529 (0.03 ) Net income per diluted common share $ 161,185 61,888 $ 2.60 Nine Months Ended October 1, 2022 Net Income Weighted- Per Share Net income per basic common share $ 480,693 60,200 $ 7.98 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 321 (0.04 ) Net income per diluted common share $ 480,693 60,521 $ 7.94 Nine Months Ended October 2, 2021 Net Income Weighted- Per Share Net income per basic common share $ 476,604 61,771 $ 7.72 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 473 (0.06 ) Net income per diluted common share $ 476,604 62,244 $ 7.66 For the three and nine months ended October 1, 2022 and October 2, 2021, the Company had fewer than one million stock options that were antidilutive due to having higher exercise prices than the Company’s average stock price during the applicable period. These securities were not included in the computation of diluted EPS. The effect of dilutive securities was calculated using the treasury stock method.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Oct. 01, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	11 Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are detailed as follows (in thousands): Currency Unrealized Gain Unrealized Gain Accumulated Other Balance at December 31, 2021 $ (99,985 ) $ (11,860 ) $ (20 ) $ (111,865 ) Other comprehensive (loss) income, net of tax (54,255 ) 1,710 20 (52,525 ) Balance at October 1, 2022 $ (154,240 ) $ (10,150 ) $ — $ (164,390 )

Retirement Plans

Retirement Plans	9 Months Ended
	Oct. 01, 2022
Retirement Benefits [Abstract]
Retirement Plans	12 Retirement Plans The Company sponsors various retirement plans. The components of net periodic benefit cost other than the service cost component are included in other income, net in the consolidated statements of operations. The summary of the components of net periodic pension costs for the plans for the three and nine months ended October 1, 2022 and October 2, 2021 is as follows (in thousands): Three Months Ended October 1, 2022 October 2, 2021 U.S. Retiree Non-U.S. U.S. Retiree Non-U.S. Service cost $ 226 $ 972 $ 198 $ 1,140 Interest cost 145 327 141 309 Expected return on plan assets (269 ) (475 ) (248 ) (459 ) Settlement loss — 139 — 102 Net amortization: Prior service (credit) cost (4 ) (31 ) (5 ) 13 Net actuarial loss — 150 8 130 Net periodic pension cost $ 98 $ 1,082 $ 94 $ 1,235 Nine Months Ended October 1, 2022 October 2, 2021 U.S. Retiree Non-U.S. U.S. Retiree Non-U.S. Service cost $ 678 $ 3,057 $ 663 $ 3,447 Interest cost 436 1,034 419 936 Expected return on plan assets (807 ) (1,505 ) (758 ) (1,389 ) Settlement loss — 139 — 102 Net amortization: Prior service credit (14 ) (100 ) (14 ) (67 ) Net actuarial loss — 476 8 653 Net periodic pension cost $ 293 $ 3,101 $ 318 $ 3,682 During fiscal year 2022, the Company expects to contribute a total of approximately $3 million to $6 million to the Company’s defined benefit plans.

Business Segment Information

Business Segment Information	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Business Segment Information	13 Business Segment Information The Company’s business activities, for which discrete financial information is available, are regularly reviewed and evaluated by the chief operating decision maker. As a result of this evaluation, the Company determined that it has two operating segments: Waters TM TM The Waters operating segment is primarily in the business of designing, manufacturing, selling and servicing LC and MS instruments, columns and other precision chemistry consumables that can be integrated and used along with other analytical instruments. The TA operating segment is primarily in the business of designing, manufacturing, selling and servicing thermal analysis, rheometry and calorimetry instruments. The Company’s two operating segments have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution; and regulatory environments. Because of these similarities, the two segments have been aggregated into one reporting segment for financial statement purposes. Please refer to the consolidated financial statements for financial information regarding the one reportable segment of the Company. Net sales for the Company’s products and services are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Product net sales: Waters instrument systems $ 274,869 $ 240,475 $ 825,677 $ 717,910 Chemistry consumables 128,096 123,045 385,661 368,478 TA instrument systems 61,958 55,613 174,055 155,722 Total product sales 464,923 419,133 1,385,393 1,242,110 Service net sales: Waters service 220,436 218,291 660,371 644,625 TA service 23,196 21,809 67,682 62,690 Total service sales 243,632 240,100 728,053 707,315 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425 Net sales are attributable to geographic areas based on the region of destination. Geographic sales information is presented below for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Net Sales: Asia: China $ 140,080 $ 115,886 $ 399,852 $ 346,030 Japan 37,095 44,293 123,222 139,702 Asia Other 102,759 94,423 289,204 268,359 Total Asia 279,934 254,602 812,278 754,091 Americas: United States 216,380 194,776 638,908 544,124 Americas Other 40,029 36,225 123,609 109,128 Total Americas 256,409 231,001 762,517 653,252 Europe 172,212 173,630 538,651 542,082 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425 Net sales by customer class are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Pharmaceutical $ 405,959 $ 398,338 $ 1,258,902 $ 1,175,191 Industrial 223,968 196,032 641,882 581,884 Academic and government 78,628 64,863 212,662 192,350 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425 Net sales for the Company recognized at a point in time versus over time are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Net sales recognized at a point in time: Instrument systems $ 336,827 $ 296,088 $ 999,732 $ 873,632 Chemistry consumables 128,096 123,045 385,661 368,478 Service sales recognized at a point in time (time & materials) 89,724 85,093 267,074 253,212 Total net sales recognized at a point in time 554,647 504,226 1,652,467 1,495,322 Net sales recognized over time: Service and software maintenance sales recognized over time (contracts) 153,908 155,007 460,979 454,103 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425

Recent Accounting Standard Chan

Recent Accounting Standard Changes and Developments	9 Months Ended
	Oct. 01, 2022
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Standard Changes and Developments	14 Recent Accounting Standard Changes and Developments Recently Issued Accounting Standards In March 2020, accounting guidance was issued that facilitates the effects of reference rate reform on financial reporting. The amendments in the update provide optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and apply to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In January of 2021, an update was issued to clarify that certain optional expedients and exceptions under the reference rate reform guidance for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. Specifically, certain provisions in the reference rate reform guidance, if elected by an entity, apply to derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. This temporary guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company may elect to apply this guidance for all contract modifications or eligible hedging relationships during that time period subject to certain criteria. The Company does not believe that it has material reference rate exposure which would require utilizing the guidance under this accounting pronouncement and if adopted does not believe that this standard would have a material impact on the Company’s financial position, results of operations and cash flows. In October 2021, accounting guidance was issued that requires acquirers in a business combination to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. The new guidance requires that at the acquisition date, the acquirer should account for the related revenue contracts in accordance with 606 as if it had originated the contracts. This guidance differs from current GAAP which requires an acquirer to recognize assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts that are accounted for in accordance with 606, at fair value on the acquisition date. This guidance is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those years. The amendments within this update should be applied prospectively to business combinations on or after the effective date of the amendments. Early adoption of the amendment is permitted, including adoption in an interim period. The applicability of this standard is dependent on there being a busin thi

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Fiscal Period	The Company’s interim fiscal quarter typically ends on the thirteenth Saturday of each quarter. Since the Company’s fiscal year end is December 31, the first and fourth fiscal quarters may have more or less than thirteen complete weeks. The Company’s third fiscal quarters for 2022 and 2021 ended on October 1, 2022 and October 2, 2021, respectively.
Basis of Accounting	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the instructions to the Quarterly Report on Form 10-Q The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities at the dates of the financial statements. Actual amounts may differ from these estimates under different assumptions or conditions. It is management’s opinion that the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K
Principles of Consolidation	The consolidated financial statements include the accounts of the Company and its subsidiaries, which are wholly owned. All inter-company balances and transactions have been eliminated.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities at the dates of the financial statements. Actual amounts may differ from these estimates under different assumptions or conditions.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks common to companies in the analytical instrument industry, including, but not limited to, global economic and financial market conditions, fluctuations in foreign currency exchange rates, fluctuations in customer demand, development by its competitors of new technological innovations, costs of developing new technologies, levels of debt and debt service requirements, risk of disruption, dependence on key personnel, protection and litigation of proprietary technology, shifts in taxable income between tax jurisdictions and compliance with regulations of the U.S. Food and Drug Administration and similar foreign regulatory authorities and agencies. Both the Company’s domestic and international operations have been and continue to be affected by the ongoing global COVID-19 COVID-19
Translation of Foreign Currencies	Translation of Foreign Currencies The functional currency of each of the Company’s foreign operating subsidiaries is the local currency of its country of domicile, except for the Company’s subsidiaries in Hong Kong, Singapore and the Cayman Islands, where the underlying transactional cash flows are denominated in currencies other than the respective local currency of domicile. The functional currency of the Hong Kong, Singapore and Cayman Islands subsidiaries is the U.S. dollar, based on the respective entity’s cash flows. For the Company’s foreign operations, assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the balance sheet date, while revenues and expenses are translated at average exchange rates prevailing during the respective period. Any resulting translation gains or losses are included in accumulated other comprehensive loss in the consolidated balance sheets.
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of October 1, 2022 and December 31, 2021, $409 million out of $445 million and $440 million out of $569 million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries. In addition, $270 million out of $445 million and $298 million out of $569 million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at October 1, 2022 and December 31, 2021, respectively.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company has very limited use of rebates and other cash considerations payable to customers and, as a result, the transaction price determination does not have any material variable consideration. The Company does not consider there to be significant concentrations of credit risk with respect to trade receivables due to the short-term nature of the balances, the Company having a large and diverse customer base, and the Company having a strong historical experience of collecting receivables with minimal defaults. As a result, credit risk is considered low across territories and trade receivables are considered to be a single class of financial asset. The allowance for credit losses is based on a number of factors and is calculated by applying a historical loss rate to trade receivable aging balances to estimate a general reserve balance along with an additional adjustment for any specific receivables with known or anticipated issues affecting the likelihood of recovery. Past due balances with a probability of default based on historical data as well as relevant available forward-looking information are included in the specific adjustment. The historical loss rate is reviewed on at least an annual basis and the allowance for credit losses is reviewed quarterly for any required adjustments. The Company does not have any off-balance Trade receivables related to instrument sales are collateralized by the instrument that is sold. If there is a risk of default related to a receivable that is collateralized, then the fair value of the collateral is calculated and adjusted for the cost to re-possess, re-sell The following is a summary of the activity of the Company’s allowance for credit losses for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Additions Deductions Balance at End Allowance for Credit Losses October 1, 2022 $ 13,228 $ 4,980 $ (4,973 ) $ 13,235 October 2, 2021 $ 14,381 $ 3,388 $ (4,107 ) $ 13,662
Other Investments	Other Investments During the nine months ended October 1, 2022, the Company sold equity investments for $10 million in cash and recorded gains on the sales of approximately $7 million in other income, net on the statement of operations. The Company also incurred $6 million in losses on equity investments recorded within other income, net on the statement of operations. During the nine months ended October 2, 2021, the Company recorded an unrealized gain on an equity security still held at the reporting date of approximately $10 million within other income, net on the statement of operations. This unrealized gain was recorded as an upward price adjustment to the carrying value of the investment due to an observable price change of a similar security.
Fair Value Measurements	Fair Value Measurements In accordance with the accounting standards for fair value measurements and disclosures, certain of the Company’s assets and liabilities are measured at fair value on a recurring basis as of October 1, 2022 and December 31, 2021. Fair values determined by Level 1 inputs utilize observable data, such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the reporting entity to develop its own assumptions. The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at October 1, 2022 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: Time deposits 876 — 876 — Waters 401(k) Restoration Plan assets 24,099 24,099 — — Foreign currency exchange contracts 278 — 278 — Interest rate cross-currency swap agreements 62,223 — 62,223 — Total $ 87,476 $ 24,099 $ 63,377 $ — Liabilities: Contingent consideration $ 1,469 $ — $ — $ 1,469 Foreign currency exchange contracts 63 — 63 — Total $ 1,532 $ — $ 63 $ 1,469 The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2021 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: U.S. Treasury securities $ 13,917 $ — $ 13,917 $ — Corporate debt securities 39,121 — 39,121 — Time deposits 19,030 — 19,030 — Waters 401(k) Restoration Plan assets 38,729 38,729 — — Foreign currency exchange contracts 504 — 504 — Total $ 111,301 $ 38,729 $ 72,572 $ — Liabilities: Contingent consideration $ 1,347 $ — $ — $ 1,347 Foreign currency exchange contracts 195 — 195 — Interest rate cross-currency swap agreements 5,363 — 5,363 — Total $ 6,905 $ — $ 5,558 $ 1,347 Fair Value of 401(k) Restoration Plan Assets The 401(k) Restoration Plan is a nonqualified defined contribution plan and the assets were held in registered mutual funds and have been classified as Level 1. The fair values of the assets in the plan are determined through market and observable sources from daily quoted prices on nationally recognized securities exchanges. Fair Value of Cash Equivalents, Investments, Foreign Currency Exchange Contracts and Interest Rate Cross-Currency Swap Agreements The fair values of the Company’s cash equivalents, investments, foreign currency exchange contracts and interest rate cross-currency swap agreements are determined through market and observable sources and have been classified as Level 2. These assets and liabilities have been initially valued at the transaction price and subsequently valued, typically utilizing third-party pricing services. The pricing services use many inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, current spot rates and other industry and economic events. The Company validates the prices provided by third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. Fair Value of Contingent Consideration The fair value of the Company’s liability for contingent consideration relates to earnout payments in connection with the December 2020 acquisition of Integrated Software Solutions (“ISS”) and is determined using a probability-weighted discounted cash flow model, which uses significant unobservable inputs, and has been classified as Level 3. Subsequent changes in the fair value of the contingent consideration liability are recorded in the results of operations. The fair value of the contingent consideration liability associated with future earnout payments is based on several factors, including the achievement of certain revenue and customer account milestones over the two years after the acquisition date and a discount rate that reflects both the likelihood of achieving the estimated future results and the Company’s creditworthiness. A change in any of these unobservable inputs can significantly change the fair value of the contingent consideration. The fair value of future contingent consideration payments related to the December 2020 acquisition of ISS was estimated to be $1 million at both October 1, 2022 and December 31, 2021. Fair Value of Other Financial Instruments The Company’s accounts receivable and accounts payable are recorded at cost, which approximates fair value due to their short-term nature. The carrying value of the Company’s variable interest rate debt approximates fair value due to the variable nature of the interest rate. The carrying value of the Company’s fixed interest rate debt was $1.3 billion at both October 1, 2022 and December 31, 2021. The fair value of the Company’s fixed interest rate debt was estimated using discounted cash flow models, based on estimated current rates offered for similar debt under current market conditions for the Company. The fair value of the Company’s fixed interest rate debt was estimated to be $1.1 billion and $1.3 billion at October 1, 2022 and December 31, 2021, respectively, using Level 2 inputs.
Derivative Transactions	Derivative Transactions The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates. The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its non-U.S. The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated and Yen-denominated Foreign Currency Exchange Contracts The Company does not specifically enter into any derivatives that hedge foreign-currency-denominated operating assets, liabilities or commitments on its balance sheet, other than a portion of certain third-party accounts receivable and accounts payable, and the Company’s net worldwide intercompany receivables and payables, which are eliminated in consolidation. The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balance to minimize some of the Company’s currency price risk exposure. The foreign currency exchange contracts are not designated for hedge accounting treatment. Principal hedged currencies include the Euro, Japanese yen, British pound, Mexican peso and Brazilian real. Interest Rate Cross-Currency Swap Agreements As of October 1, 2022, the Company had three-year interest rate cross-currency swap derivative agreements with an aggregate notional value of $585 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated and Yen-denominated The Company’s foreign currency exchange contracts and interest rate cross-currency swap agreements included in the consolidated balance sheets are classified as follows (in thousands): October 1, 2022 December 31, 2021 Notional Value Fair Value Notional Value Fair Value Foreign currency exchange contracts: Other current assets $ 42,690 $ 278 $ 55,309 $ 504 Other current liabilities $ 17,000 $ 63 $ 9,000 $ 195 Interest rate cross-currency swap agreements: Other assets $ 585,000 $ 62,223 $ — $ — Other liabilities — — 230,000 5,363 Accumulated other comprehensive income (loss) $ 57,869 $ (15,944 ) The following is a summary of the activity included in the consolidated statements of operations and statements of comprehensive income related to the foreign currency exchange contracts and interest rate cross-currency swap agreements (in thousands): Financial Statement Classification Three Months Ended Nine Months Ended October 1, October 2, October 1, October 2, Foreign currency exchange contracts: Realized (losses) gains on closed contracts Cost of sales $ (3,811 ) $ (774 ) $ (6,603 ) $ 681 Unrealized gains (losses) on open contracts Cost of sales 461 (933 ) (93 ) (2,256 ) Cumulative net pre-tax Cost of sales $ (3,350 ) $ (1,707 ) $ (6,696 ) $ (1,575 ) Interest rate cross-currency swap agreements: Interest earned Interest income $ 2,362 $ 2,305 $ 6,214 $ 9,505 Unrealized gains on open contracts Other comprehensive income $ 31,108 $ 7,762 $ 73,812 $ 24,777
Stockholders' Equity	Stockholders’ Equity In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock over a two-year pre-existing program. In Dec e s.
Product Warranty Costs	Product Warr a s The Compan y accrues estimated product warranty costs at the time of sale, which are included in cost of sales in the consolidated statements of operations. While the Company en g The following is a summary of the activity of the Company’s accrued warranty liability for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Accruals for Settlements Balance at Accrued warranty liability: October 1, 2022 $ 10,718 $ 6,606 $ (6,663 ) $ 10,661 October 2, 2021 $ 10,950 $ 6,537 $ (6,991 ) $ 10,496
Other Items	Other Items During the nine months ended October 1, 2022, the Company completed an asset acquisition in which the charge detection mass spectrometry technology (“CDMS technology”) assets of Megadalton Solutions, Inc. (“Megadalton”) were acquired for approximately $10 million in total purchase price, of which $5 million was paid at closing and the remaining $4 million will be paid in the future at various dates through 2029. This CDMS technology makes it possible to analyze extremely large proteins and protein complexes used in cell and gene therapies that would otherwise be difficult to analyze with conventional mass spectrometry. Once this technology is further developed, it will extend the capabilities of our mass spectrometry portfolio for a broader set of applications and as such the cost of this technology asset has been accounted for as Acquired In-Process

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Summary of Activity of Company's Allowance for Doubtful Accounts	The following is a summary of the activity of the Company’s allowance for credit losses for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Additions Deductions Balance at End Allowance for Credit Losses October 1, 2022 $ 13,228 $ 4,980 $ (4,973 ) $ 13,235 October 2, 2021 $ 14,381 $ 3,388 $ (4,107 ) $ 13,662
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at October 1, 2022 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: Time deposits 876 — 876 — Waters 401(k) Restoration Plan assets 24,099 24,099 — — Foreign currency exchange contracts 278 — 278 — Interest rate cross-currency swap agreements 62,223 — 62,223 — Total $ 87,476 $ 24,099 $ 63,377 $ — Liabilities: Contingent consideration $ 1,469 $ — $ — $ 1,469 Foreign currency exchange contracts 63 — 63 — Total $ 1,532 $ — $ 63 $ 1,469 The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2021 (in thousands): Total at Quoted Prices for Identical (Level 1) Significant Significant (Level 3) Assets: U.S. Treasury securities $ 13,917 $ — $ 13,917 $ — Corporate debt securities 39,121 — 39,121 — Time deposits 19,030 — 19,030 — Waters 401(k) Restoration Plan assets 38,729 38,729 — — Foreign currency exchange contracts 504 — 504 — Total $ 111,301 $ 38,729 $ 72,572 $ — Liabilities: Contingent consideration $ 1,347 $ — $ — $ 1,347 Foreign currency exchange contracts 195 — 195 — Interest rate cross-currency swap agreements 5,363 — 5,363 — Total $ 6,905 $ — $ 5,558 $ 1,347
Summary of Foreign Currency Exchange Contracts and Interest Rate Cross-Currency Swap Agreements	The Company’s foreign currency exchange contracts and interest rate cross-currency swap agreements included in the consolidated balance sheets are classified as follows (in thousands): October 1, 2022 December 31, 2021 Notional Value Fair Value Notional Value Fair Value Foreign currency exchange contracts: Other current assets $ 42,690 $ 278 $ 55,309 $ 504 Other current liabilities $ 17,000 $ 63 $ 9,000 $ 195 Interest rate cross-currency swap agreements: Other assets $ 585,000 $ 62,223 $ — $ — Other liabilities — — 230,000 5,363 Accumulated other comprehensive income (loss) $ 57,869 $ (15,944 )
Gains (Losses) on Foreign Exchange Contracts	The following is a summary of the activity included in the consolidated statements of operations and statements of comprehensive income related to the foreign currency exchange contracts and interest rate cross-currency swap agreements (in thousands): Financial Statement Classification Three Months Ended Nine Months Ended October 1, October 2, October 1, October 2, Foreign currency exchange contracts: Realized (losses) gains on closed contracts Cost of sales $ (3,811 ) $ (774 ) $ (6,603 ) $ 681 Unrealized gains (losses) on open contracts Cost of sales 461 (933 ) (93 ) (2,256 ) Cumulative net pre-tax Cost of sales $ (3,350 ) $ (1,707 ) $ (6,696 ) $ (1,575 ) Interest rate cross-currency swap agreements: Interest earned Interest income $ 2,362 $ 2,305 $ 6,214 $ 9,505 Unrealized gains on open contracts Other comprehensive income $ 31,108 $ 7,762 $ 73,812 $ 24,777
Summary of Activity of Company's Accrued Warranty Liability	The following is a summary of the activity of the Company’s accrued warranty liability for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): Balance at Accruals for Settlements Balance at Accrued warranty liability: October 1, 2022 $ 10,718 $ 6,606 $ (6,663 ) $ 10,661 October 2, 2021 $ 10,950 $ 6,537 $ (6,991 ) $ 10,496

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Summary of Activity of Deferred Revenue and Customer Advances	The following is a summary of the activity of the Company’s deferred revenue and customer advances for the nine months ended October 1, 2022 and October 2, 2021 (in thousands): October 1, 2022 October 2, 2021 Balance at the beginning of the period $ 273,598 $ 239,759 Recognition of revenue included in balance at beginning of the period (213,527 ) (197,279 ) Revenue deferred during the period, net of revenue recognized 243,853 264,184 Balance at the end of the period $ 303,924 $ 306,664
Schedule of Amount of Deferred Revenue and Customer Advances	The amount of deferred revenue and customer advances equals the transaction price allocated to unfulfilled performance obligations for the period presented. Such amounts are expected to be recognized in the future as follows (in thousands): October 1, 2022 Deferred revenue and customer advances expected to be recognized in: One year or less $ 248,884 13 31,632 25 months and beyond 23,408 Total $ 303,924

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Oct. 01, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Securities Reconciliation	The Company’s marketable securities within cash equivalents and investments included in the consolidated balance sheets are detailed as follows (in thousands): October 1, 2022 Amortized Unrealized Unrealized Fair Time deposits 876 — — 876 Total $ 876 $ — $ — $ 876 Amounts included in: Investments 876 — — 876 Total $ 876 $ — $ — $ 876 December 31, 2021 Amortized Unrealized Unrealized Fair U.S. Treasury securities $ 13,929 $ — $ (12 ) $ 13,917 Corporate debt securities 39,135 — (14 ) 39,121 Time deposits 19,030 — — 19,030 Total $ 72,094 $ — $ (26 ) $ 72,068 Amounts included in: Cash equivalents $ 4,017 $ — $ — $ 4,017 Investments 68,077 — (26 ) 68,051 Total $ 72,094 $ — $ (26 ) $ 72,068
Investments Classified By Contractual Maturity Date	The estimated fair value of marketable debt securities by maturity date is as follows (in thousands): October 1, 2022 December 31, 2021 Due in one year or less $ 876 $ 71,066 Due after one year through three years — 1,002 Total $ 876 $ 72,068

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 01, 2022
Inventory Disclosure [Abstract]
Inventory, Net of Reserves	Inventories are classified as follows (in thousands): October 1, 2022 December 31, 2021 Raw materials $ 186,958 $ 165,240 Work in progress 23,577 19,726 Finished goods 231,701 171,129 Total inventories $ 442,236 $ 356,095

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The Company’s intangible assets included in the consolidated balance sheets are detailed as follows (dollars in thousands): October 1, 2022 December 31, 2021 Gross Accumulated Weighted- Gross Accumulated Weighted- Capitalized software $ 525,196 $ 391,250 5 years $ 575,658 $ 420,862 5 years Purchased intangibles 193,056 160,972 11 years 201,302 163,752 11 years Trademarks 9,680 — — 9,680 — — Licenses 12,739 5,848 6 years 12,635 6,199 7 years Patents and other intangibles 100,255 69,427 8 years 102,353 68,414 8 years Total $ 840,926 $ 627,497 7 years $ 901,628 $ 659,227 7 years

Debt (Tables)

Debt (Tables)	9 Months Ended
	Oct. 01, 2022
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The outstanding October 1, 2022 December 31, 2021 Senior unsecured notes - Series I - 3.13%, due May 2023 $ 50,000 $ — Total notes payable and debt, current 50,000 — Senior unsecured notes - Series G - 3.92%, due June 2024 50,000 50,000 Senior unsecured notes - Series H - floating rate*, due June 2024 50,000 50,000 Senior unsecured notes - Series I - 3.13%, due May 2023 — 50,000 Senior unsecured notes - Series K - 3.44%, due May 2026 160,000 160,000 Senior unsecured notes - Series L - 3.31%, due September 2026 200,000 200,000 Senior unsecured notes - Series M - 3.53%, due September 2029 300,000 300,000 Senior unsecured notes - Series N - 1.68%, due March 2026 100,000 100,000 Senior unsecured notes - Series O - 2.25%, due March 2031 400,000 400,000 Credit agreement 240,000 210,000 Unamortized debt issuance costs (5,374 ) (6,130 ) Total long-term debt 1,494,626 1,513,870 Total debt $ 1,544,626 $ 1,513,870 * Series H senior unsecured notes bear interest at a 3-month

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Oct. 01, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense	The consolidated statements of operations for the three and nine months ended October 1, 2022 and October 2, 2021 include the following stock-based compensation expense related to stock option awards, restricted stock awards, restricted stock unit awards, performance stock unit awards and the employee stock purchase plan (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Cost of sales $ 478 $ 468 $ 2,420 $ 1,828 Selling and administrative expenses 8,174 4,116 23,607 15,810 Research and development expenses 1,555 1,769 4,902 4,311 Total stock-based compensation $ 10,207 $ 6,353 $ 30,929 $ 21,949
Summary of Relevant Data Used to Determine the Value of Stock Options Granted During the Period	The relevant data used to determine the value of the stock options granted during the nine months ended October 1, 2022 and October 2, 2021 are as follows: Nine Months Ended Options Issued and Significant Assumptions Used to Estimate Option Fair Values October 1, 2022 October 2, 2021 Options issued in thousands 138 160 Risk-free interest rate 2.0 % 0.8 % Expected life in years 6 6 Expected volatility 30.7 % 32.4 % Expected dividends — —
Summary of Stock Options Outstanding Roll Forward	Nine Months Ended Weighted-Average Exercise Price and Fair Value of Options on the Date of Grant October 1, 2022 October 2, 2021 Exercise price $ 321.12 $ 281.23 Fair value $ 107.95 $ 91.46
Summary of Stock Options Outstanding by Exercise Price Range	The following table summarizes stock option activity for the plans for the nine months ended October 1, 2022 (in thousands, except per share data): Number of Shares Exercise Price per Share Weighted-Average Outstanding at December 31, 2021 691 $ 88.71 to $371.64 $ 202.24 Granted 138 $ 270.49 to $364.59 $ 321.12 Exercised (167 ) $ 88.71 to $279.90 $ 168.37 Canceled (40 ) $ 188.63 to $364.59 $ 253.23 Outstanding at October 1, 2022 622 $ 88.71 to $371.64 $ 234.43
Summary of Restricted Stock Units Unvested Roll Forward	The following table summarizes the unvested restricted stock unit award activity for the nine months ended October 1, 2022 (in thousands, except per share data): Shares Weighted-Average Unvested at December 31, 2021 245 $ 234.97 Granted 98 $ 322.99 Vested (76 ) $ 219.30 Forfeited (23 ) $ 256.22 Unvested at October 1, 2022 244 $ 273.20
Summary of Relevant Data Used to Determine the Value of Performance Shares	The relevant data used to determine the value of the performance stock units granted during the nine months ended October 1, 2022 and October 2, 2021 are as Nine Months Ended Performance Stock Units Issued and Significant Assumptions Used to Estimate October 1, 2022 October 2, 2021 Performance stock units issued (in thousands) 40 41 Risk-free interest rate 1.6 % 0.2 % Expected life in years 2.9 2.9 Expected volatility 25.4 % 38.7 % Average volatility of peer companies 34.5 % 34.7 % Correlation coefficient 43.0 % 45.8 % Expected dividends — —
Summary of Performance Stock Units Unvested Roll Forward	The following table summarizes the unvested performance stock unit award activity for the nine months ended October 1, 2022 (in thousands, except per share data): Shares Weighted-Average Unvested at December 31, 2021 87 $ 285.73 Granted 40 $ 313.21 Vested (24 ) $ 308.71 Forfeited 8 $ 381.32 Unvested at October 1, 2022 111 $ 297.55

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Earnings Per Share Reconciliation	Basic and diluted EPS calculations are detailed as follows (in thousands, except per share data): Three Months Ended October 1, 2022 Net Income Weighted- Per Share Net income per basic common share $ 155,998 59,801 $ 2.61 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 280 (0.01 ) Net income per diluted common share $ 155,998 60,081 $ 2.60 Three Months Ended October 2, 2021 Net Income Weighted- Per Share Net income per basic common share $ 161,185 61,359 $ 2.63 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 529 (0.03 ) Net income per diluted common share $ 161,185 61,888 $ 2.60 Nine Months Ended October 1, 2022 Net Income Weighted- Per Share Net income per basic common share $ 480,693 60,200 $ 7.98 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 321 (0.04 ) Net income per diluted common share $ 480,693 60,521 $ 7.94 Nine Months Ended October 2, 2021 Net Income Weighted- Per Share Net income per basic common share $ 476,604 61,771 $ 7.72 Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities — 473 (0.06 ) Net income per diluted common share $ 476,604 62,244 $ 7.66

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Oct. 01, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The components of accumulated other comprehensive loss are detailed as follows (in thousands): Currency Unrealized Gain Unrealized Gain Accumulated Other Balance at December 31, 2021 $ (99,985 ) $ (11,860 ) $ (20 ) $ (111,865 ) Other comprehensive (loss) income, net of tax (54,255 ) 1,710 20 (52,525 ) Balance at October 1, 2022 $ (154,240 ) $ (10,150 ) $ — $ (164,390 )

Retirement Plans (Tables)

Retirement Plans (Tables)	9 Months Ended
	Oct. 01, 2022
Retirement Benefits [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost	The summary of the components of net periodic pension costs for the plans for the three and nine months ended October 1, 2022 and October 2, 2021 is as follows (in thousands): Three Months Ended October 1, 2022 October 2, 2021 U.S. Retiree Non-U.S. U.S. Retiree Non-U.S. Service cost $ 226 $ 972 $ 198 $ 1,140 Interest cost 145 327 141 309 Expected return on plan assets (269 ) (475 ) (248 ) (459 ) Settlement loss — 139 — 102 Net amortization: Prior service (credit) cost (4 ) (31 ) (5 ) 13 Net actuarial loss — 150 8 130 Net periodic pension cost $ 98 $ 1,082 $ 94 $ 1,235 Nine Months Ended October 1, 2022 October 2, 2021 U.S. Retiree Non-U.S. U.S. Retiree Non-U.S. Service cost $ 678 $ 3,057 $ 663 $ 3,447 Interest cost 436 1,034 419 936 Expected return on plan assets (807 ) (1,505 ) (758 ) (1,389 ) Settlement loss — 139 — 102 Net amortization: Prior service credit (14 ) (100 ) (14 ) (67 ) Net actuarial loss — 476 8 653 Net periodic pension cost $ 293 $ 3,101 $ 318 $ 3,682

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Summary of Net Sales for Company's Products and Services	Net sales for the Company’s products and services are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Product net sales: Waters instrument systems $ 274,869 $ 240,475 $ 825,677 $ 717,910 Chemistry consumables 128,096 123,045 385,661 368,478 TA instrument systems 61,958 55,613 174,055 155,722 Total product sales 464,923 419,133 1,385,393 1,242,110 Service net sales: Waters service 220,436 218,291 660,371 644,625 TA service 23,196 21,809 67,682 62,690 Total service sales 243,632 240,100 728,053 707,315 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425
Summary of Geographic Sales Information	Net sales are attributable to geographic areas based on the region of destination. Geographic sales information is presented below for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Net Sales: Asia: China $ 140,080 $ 115,886 $ 399,852 $ 346,030 Japan 37,095 44,293 123,222 139,702 Asia Other 102,759 94,423 289,204 268,359 Total Asia 279,934 254,602 812,278 754,091 Americas: United States 216,380 194,776 638,908 544,124 Americas Other 40,029 36,225 123,609 109,128 Total Americas 256,409 231,001 762,517 653,252 Europe 172,212 173,630 538,651 542,082 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425
Summary of Net Sales by Customer Class	Net sales by customer class are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Pharmaceutical $ 405,959 $ 398,338 $ 1,258,902 $ 1,175,191 Industrial 223,968 196,032 641,882 581,884 Academic and government 78,628 64,863 212,662 192,350 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425
Summary of Net Sales of Company Recognized at a Point in Time Versus Over Time	Net sales for the Company recognized at a point in time versus over time are as follows for the three and nine months ended October 1, 2022 and October 2, 2021 (in thousands): Three Months Ended Nine Months Ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Net sales recognized at a point in time: Instrument systems $ 336,827 $ 296,088 $ 999,732 $ 873,632 Chemistry consumables 128,096 123,045 385,661 368,478 Service sales recognized at a point in time (time & materials) 89,724 85,093 267,074 253,212 Total net sales recognized at a point in time 554,647 504,226 1,652,467 1,495,322 Net sales recognized over time: Service and software maintenance sales recognized over time (contracts) 153,908 155,007 460,979 454,103 Total net sales $ 708,555 $ 659,233 $ 2,113,446 $ 1,949,425

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Jul. 02, 2022	Dec. 31, 2021	Jan. 31, 2019
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Cash equivalents description			Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments.
Cash, cash equivalents and investments	$ 445,000,000		$ 445,000,000			$ 569,000,000
Contingent consideration	1,469,000		1,469,000			1,347,000
Long-term debt	1,494,626,000		$ 1,494,626,000			1,513,870,000
Foreign currency exposure			The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates.
Maturity period of foreign exchange contracts			The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balance to minimize some of the Company’s currency price risk exposure. The foreign currency exchange contracts are not designated for hedge accounting treatment.
Treasury stock	155,223,000	$ 146,051,000	$ 477,167,000	$ 492,695,000
Unrealized gain on an equity security			6,000,000	$ 10,000,000
Purchase price			10,000,000
Maximum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Purchase price			5,000,000
Minimum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Purchase price			4,000,000
Other Income [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Proceeds from sale of equity method investment			10,000,000
Gain (Loss) on Investments			7,000,000
Cross Currency Interest Rate Contract [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Notional value, derivative asset	585,000,000		$ 585,000,000
Programs Authorized by Board of Directors [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Treasury stock shares acquired			1.5	1.5
Treasury stock			$ 467,000,000	$ 484,000,000
Related to Vesting of Restricted Stock Units [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Treasury stock			$ 11,000,000
January 2019 Program [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Stock repurchase program authorization amount							$ 4,000,000,000
Treasury stock shares acquired			14.6
Treasury stock				3,600,000,000
Stock repurchase program remaining amount authorized for future purchases					$ 418,000,000
Treasury Stock [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Treasury stock	155,223,000	$ 146,051,000	$ 477,167,000	$ 492,695,000
Accrued treasury stock repurchases	9,000,000		9,000,000
Held In Currencies Other Than Us Dollars [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Cash, cash equivalents and investments	270,000,000		270,000,000			298,000,000
Unsecured Debt [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Long-term debt	1,300,000,000		1,300,000,000
Unsecured Debt [Member] | Fixed Interest Rate [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Contingent consideration	1,000,000		1,000,000
Long-term debt	1,300,000,000		1,300,000,000			1,300,000,000
Fair value of fixed interest rate debt	1,100,000,000		1,100,000,000			1,300,000,000
Held By Foreign Subsidiaries [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Line Items]
Cash, cash equivalents and investments	$ 409,000,000		$ 409,000,000			$ 440,000,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Allowance for Doubtful Accounts Roll Forward (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance	$ 13,228	$ 14,381
Additions	4,980	3,388
Deductions	(4,973)	(4,107)
Ending balance	$ 13,235	$ 13,662

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities	$ 876	$ 72,068
Waters 401(k) Restoration Plan assets	24,099	38,729
Total	87,476	111,301
Contingent consideration	1,469	1,347
Total	1,532	6,905
Foreign Currency Exchange Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	278	504
Foreign currency exchange contracts	63	195
Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	62,223
Foreign currency exchange contracts		5,363
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities		13,917
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities		39,121
Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities	876	19,030
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Waters 401(k) Restoration Plan assets	24,099	38,729
Total	24,099	38,729
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	63,377	72,572
Total	63	5,558
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member] | Foreign Currency Exchange Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	278	504
Foreign currency exchange contracts	63	195
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member] | Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	62,223
Foreign currency exchange contracts		5,363
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member] | US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities		13,917
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities		39,121
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 2) [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities	876	19,030
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	1,469	1,347
Total	$ 1,469	$ 1,347

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies - Fair Value of Forward Foreign Exchange Contracts (Detail) - USD ($)	Oct. 01, 2022	Dec. 31, 2021
Foreign Currency Exchange Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	$ 278,000	$ 504,000
Fair value, derivative liability	63,000	195,000
Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional value, derivative asset	585,000,000
Fair value, derivative asset	62,223,000
Fair value, derivative liability		5,363,000
Other Current Assets [Member] | Foreign Currency Exchange Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional value, derivative asset	42,690,000	55,309,000
Fair value, derivative asset	278,000	504,000
Other Current Liabilities [Member] | Foreign Currency Exchange Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional value, derivative liability	17,000,000	9,000,000
Fair value, derivative liability	63,000	195,000
Other Assets [Member] | Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional value, derivative asset	585,000,000
Fair value, derivative asset	62,223,000
Other Liabilities [Member] | Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional value, derivative liability		230,000,000
Fair value, derivative liability		5,363,000
Accumulated Other Comprehensive Income (Loss) [Member] | Cross Currency Interest Rate Contract [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, derivative asset	$ 57,869,000	$ (15,944,000)

Basis of Presentation and Sum_8

Basis of Presentation and Summary of Significant Accounting Policies - Gains (Losses) on Foreign Exchange Contracts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Cost of Sales [Member] | Foreign Currency Exchange Contract [Member]
Derivative [Line Items]
Realized (losses) gains on closed contracts	$ (3,811)	$ (774)	$ (6,603)	$ 681
Unrealized gains (losses) on open contracts	461	(933)	(93)	(2,256)
Cumulative net pre-tax losses	(3,350)	(1,707)	(6,696)	(1,575)
Interest Income [Member] | Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Interest earned	2,362	2,305	6,214	9,505
Other comprehensive income [Member] | Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Unrealized gains on open contracts	$ 31,108	$ 7,762	$ 73,812	$ 24,777

Basis of Presentation and Sum_9

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Activity of Company's Accrued Warranty Liability (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at Beginning of Period	$ 10,718	$ 10,950
Accruals for Warranties	6,606	6,537
Settlements Made	(6,663)	(6,991)
Balance at End of Period	$ 10,661	$ 10,496

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Millions	Oct. 01, 2022	Dec. 31, 2021
Revenue Recognition [Line Items]
Deferred revenue and customer advances	$ 55	$ 46

Revenue Recognition - Summary o

Revenue Recognition - Summary of Activity of the Company's Deferred Revenue and Customer Advances (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Balance at the beginning of the period	$ 273,598	$ 239,759
Recognition of revenue included in balance at beginning of the period	(213,527)	(197,279)
Revenue deferred during the period, net of revenue recognized	243,853	264,184
Balance at the end of the period	$ 303,924	$ 306,664

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Estimated Amount of Deferred Revenue and Customer Advances (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Revenue Recognition [Line Items]
Deferred revenue and customer advances expected to be recognized	$ 248,884	$ 227,561
Deferred revenue and customer advances expected to be recognized	303,924
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue Recognition [Line Items]
Deferred revenue and customer advances expected to be recognized	$ 248,884
Deferred revenue and customer advances recognition period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue Recognition [Line Items]
Deferred revenue and customer advances expected to be recognized	$ 31,632
Deferred revenue and customer advances recognition period	24 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue Recognition [Line Items]
Deferred revenue and customer advances expected to be recognized	$ 23,408
Deferred revenue and customer advances recognition period	25 months

Marketable Securities - Schedul

Marketable Securities - Schedule of Available-for-Sale Securities Reconciliation (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 876	$ 72,094
Unrealized Loss		(26)
Fair Value	876	72,068
US Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		13,929
Unrealized Loss		(12)
Fair Value		13,917
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		39,135
Unrealized Loss		(14)
Fair Value		39,121
Time Deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	876	19,030
Fair Value	876	19,030
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		4,017
Fair Value		4,017
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	876	68,077
Unrealized Loss		(26)
Fair Value	$ 876	$ 68,051

Marketable Securities - Investm

Marketable Securities - Investments Classified By Contractual Maturity Date (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Due in one year or less	$ 876	$ 71,066
Due after one year through three years		1,002
Total	$ 876	$ 72,068

Inventories - Inventory, Net of

Inventories - Inventory, Net of Reserves (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Inventory, Net, Items Net of Reserve Alternative [Abstract]
Raw materials	$ 186,958	$ 165,240
Work in progress	23,577	19,726
Finished goods	231,701	171,129
Total inventories	$ 442,236	$ 356,095

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		21 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Oct. 02, 2022	Dec. 31, 2021
Finite Lived And Indefinite Lived Intangible Assets [Line Items]
Goodwill	$ 420,257		$ 420,257			$ 437,865
Goodwill foreign currency translation adjustments			18,000
Intangible assets, gross foreign currency translation adjustments			98,000
Intangible assets, accumulated amortization foreign currency translation adjustments			76,000
Amortization expense	15,000	$ 15,000	45,000	$ 45,000
Future amortization expense, year 1	62,000		62,000
Future amortization expense, year 2	62,000		62,000
Future amortization expense, year 3	62,000		62,000
Future amortization expense, year 4	62,000		62,000
Future amortization expense, year 5	62,000		62,000
Intangible assets other than goodwill capitalized during the period	$ 14,000	$ 18,000	$ 38,000		$ 45,000

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 01, 2022	Dec. 31, 2021
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 840,926	$ 901,628
Accumulated Amortization	$ 627,497	$ 659,227
Weighted-Average Amortization Period	7 years	7 years
Trademarks [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 9,680	$ 9,680
Software Development [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	525,196	575,658
Accumulated Amortization	$ 391,250	$ 420,862
Weighted-Average Amortization Period	5 years	5 years
Purchased Intangibles [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 193,056	$ 201,302
Accumulated Amortization	$ 160,972	$ 163,752
Weighted-Average Amortization Period	11 years	11 years
Licensing Agreements [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 12,739	$ 12,635
Accumulated Amortization	$ 5,848	$ 6,199
Weighted-Average Amortization Period	6 years	7 years
Patents and Other Intangibles [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 100,255	$ 102,353
Accumulated Amortization	$ 69,427	$ 68,414
Weighted-Average Amortization Period	8 years	8 years

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2022	Dec. 31, 2021	Nov. 30, 2017
Debt Instrument [Line Items]
Debt facility fee		The interest rates applicable to the 2021 Credit Agreement are, at the Company’s option, equal to either the alternate base rate (which is a rate per annum equal to the greatest of (1) the prime rate in effect on such day, (2) the Federal Reserve Bank of New York Rate on such day plus 1/2 of 1% per annum and (3) the adjusted LIBO rate on such day (or if such day is not a business day, the immediately preceding business day) for a deposit in U.S. dollars with a maturity of one month plus 1% per annum) or the applicable 1, 3 or 6 month adjusted LIBO rate or EURIBO rate for Euro-denominated loans, in each case, plus an interest rate margin based upon the Company’s leverage ratio, which can range between 0 and 12.5 basis points for alternate base rate loans and between 80 and 112.5 basis points for LIBO rate or EURIBO rate loans. The facility fee on the 2021 Credit Agreement ranges between 7.5 and 25 basis points per annum, based on the leverage ratio, of the amount of the revolving facility commitments and the outstanding term loan.
Long-term debt		$ 1,494,626,000	$ 1,513,870,000
Line of credit maximum borrowing capacity		111,000,000	$ 121,000,000
Cross Currency Interest Rate Contract [Member]
Debt Instrument [Line Items]
Notional value, derivative asset		$ 585,000,000
Derivative instrument, term		3 years
Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Interest rate terms on debt		The interest rates applicable to the 2021 Credit Agreement are, at the Company’s option, equal to either the alternate base rate (which is a rate per annum equal to the greatest of (1) the prime rate in effect on such day, (2) the Federal Reserve Bank of New York Rate on such day plus 1/2 of 1% per annum and (3) the adjusted LIBO rate on such day (or if such day is not a business day, the immediately preceding business day) for a deposit in U.S. dollars with a maturity of one month plus 1% per annum) or the applicable 1, 3 or 6 month adjusted LIBO rate or EURIBO rate for Euro-denominated loans, in each case, plus an interest rate margin based upon the Company’s leverage ratio, which can range between 0 and 12.5 basis points for alternate base rate loans and between 80 and 112.5 basis points for LIBO rate or EURIBO rate loans. The facility fee on the 2021 Credit Agreement ranges between 7.5 and 25 basis points per annum, based on the leverage ratio, of the amount of the revolving facility commitments and the outstanding term loan.
Debt covenant description		The 2021 Credit Agreement requires that the Company comply with an interest coverage ratio test of not less than 3.50:1 as of the end of any fiscal quarter for any period of four consecutive fiscal quarters and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, the 2021 Credit Agreement includes negative covenants, affirmative covenants, representations and warranties and events of default that are customary for investment grade credit facilities.
Unused borrowing capacity		$ 1,600,000,000
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt covenant description		These senior unsecured notes require that the Company comply with an interest coverage ratio test of not less than 3.50:1 for any period of four consecutive fiscal quarters and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, these senior unsecured notes include customary negative covenants, affirmative covenants, representations and warranties and events of default.
Long-term debt		$ 1,300,000,000
Call feature on debt instrument		The Company may prepay all or some of the senior unsecured notes at any time in an amount not less than 10% of the aggregate principal amount outstanding, plus the applicable make-whole amount or prepayment premium for the Series H senior unsecured note.
Debt instrument percentage of the amount to be prepaid		10%
Debt instrument interest coverage ratio		3.50%
Debt instrument leverage ratio		3.50%
Credit Agreements and Unsecured Debt [Member]
Debt Instrument [Line Items]
Weighted-average interest rate		3.24%	2.74%
Revolving Facilities [Member] | Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Face value of debt				$ 1,800,000,000
2021 Credit facility
Debt Instrument [Line Items]
Long term debt gross		$ 240,000,000	$ 210,000,000
Debt Instrument, Term	5 years

Debt - Summary of Outstanding D

Debt - Summary of Outstanding Debt (Detail) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total notes payable and debt, current	$ 50,000	$ 0
Unamortized debt issuance costs	(5,374)	(6,130)
Total long-term debt	1,494,626	1,513,870
Total debt	1,544,626	1,513,870
Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term debt	240,000	210,000
Senior Unsecured Notes Series G [Member]
Debt Instrument [Line Items]
Total notes payable and debt, current	50,000	50,000
Senior Unsecured Notes Series H [Member]
Debt Instrument [Line Items]
Total notes payable and debt, current	50,000	50,000
Senior Unsecured Notes Series I [Member]
Debt Instrument [Line Items]
Total notes payable and debt, current	50,000
Long-term debt		50,000
Senior Unsecured Notes Series K [Member]
Debt Instrument [Line Items]
Long-term debt	160,000	160,000
Senior Unsecured Notes Series L [Member]
Debt Instrument [Line Items]
Long-term debt	200,000	200,000
Senior Unsecured Notes Series M [Member]
Debt Instrument [Line Items]
Long-term debt	300,000	300,000
Senior Unsecured Notes Series N [Member]
Debt Instrument [Line Items]
Long-term debt	100,000	100,000
Senior Unsecured Notes Series O [Member]
Debt Instrument [Line Items]
Long-term debt	$ 400,000	$ 400,000

Debt - Summary of Outstanding_2

Debt - Summary of Outstanding Debt (Parenthetical) (Detail)	9 Months Ended	12 Months Ended
	Oct. 01, 2022	Dec. 31, 2021
Senior Unsecured Notes Series G [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	3.92%	3.92%
Senior Unsecured Notes Series H [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Interest rate margin	1.25%	1.25%
Senior Unsecured Notes Series I [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	3.13%	3.13%
Senior Unsecured Notes Series K [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	3.44%	3.44%
Senior Unsecured Notes Series L [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	3.31%	3.31%
Senior Unsecured Notes Series M [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	3.53%	3.53%
Senior Unsecured Notes Series N [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	1.68%	1.68%
Senior Unsecured Notes Series O [Member]
Debt Instrument [Line Items]
Stated interest rate on debt instrument	2.25%	2.25%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Income Taxes [Line Items]
Income tax holiday amount			$ 15	$ 13
Income tax holiday per share benefit			$ 0.25	$ 0.2
Effective income tax rate	14.90%	11.80%	14.50%	14%
Gross unrecognized tax benefit would impact the Company's effective tax rate		$ 29		$ 29
Maximum [Member]
Income Taxes [Line Items]
Expected change in unrecognized tax benefits in the next twelve months	$ 18		$ 18
United States [Member]
Income Taxes [Line Items]
Statutory tax rate			21%
Ireland [Member]
Income Taxes [Line Items]
Statutory tax rate			12.50%
U.K [Member]
Income Taxes [Line Items]
Statutory tax rate			19%
Singapore [Member]
Income Taxes [Line Items]
Statutory tax rate			17%
Singapore [Member] | April Two Thousand And Twenty One To March Two Thousand And Twenty Six [Member] | New Contractual Arrangement [Member]
Income Taxes [Line Items]
Statutory tax rate			5%
Singapore [Member] | Contractual Tax Rate Singapore [Member]
Income Taxes [Line Items]
Marginal effective income tax rate			0%

Other Commitments and Conting_2

Other Commitments and Contingencies - Additional Information (Detail) $ in Millions	9 Months Ended
	Oct. 01, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Future Minimum License Fees Payable	Future minimum license fees payable under existing license agreements as of October 1, 2022 are immaterial for the years ended December 31, 2022 and thereafter.
Potentials Payments Under Licensing Arrangements	$ 2

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) shares in Millions	9 Months Ended
	Oct. 01, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant | shares	6.5
Performance Stock Unit Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of shares granted	$ 313.21
Performance Stock Unit Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights	0%
Performance Stock Unit Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights	200%
Restricted Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of shares granted	$ 364.59
Award vesting period	5 years
Equity Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years
Award expiration period	10 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 10,207	$ 6,353	$ 30,929	$ 21,949
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	478	468	2,420	1,828
Selling and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	8,174	4,116	23,607	15,810
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 1,555	$ 1,769	$ 4,902	$ 4,311

Stock-Based Compensation - Rele

Stock-Based Compensation - Relevant Data Used to Determine the Value of Stock Options Granted During the Period (Detail) - Equity Option [Member] - USD ($) shares in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Options Issued and Significant Assumptions Used to Estimate Option Fair Values
Options issued	138	160
Fair value assumptions, risk free interest rate	2%	0.80%
Fair value assumptions, expected life in years	6 years	6 years
Fair value assumptions, expected volatility	30.70%	32.40%
Fair value assumptions, expected dividends
Weighted-Average Exercise Price and Fair Value of Options on the Date of Grant
Weighted-average exercise price of options granted	$ 321.12	$ 281.23
Weighted-average grant date fair value of options granted	$ 107.95	$ 91.46

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Outstanding Roll Forward (Detail) - Equity Option [Member] - $ / shares shares in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at December 31, 2021	691
Granted	138	160
Exercised	(167)
Canceled	(40)
Outstanding at July 2, 2022	622
Weighted-average exercise price of options outstanding at beginning of period	$ 202.24
Weighted-average exercise price of options granted	321.12	$ 281.23
Weighted-average exercise price of options exercised	168.37
Weighted average exercise price of options canceled	253.23
Weighted-average exercise price of options outstanding at end of period	234.43
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average exercise price of options outstanding at beginning of period	88.71
Weighted-average exercise price of options granted	270.49
Weighted-average exercise price of options exercised	88.71
Weighted average exercise price of options canceled	188.63
Weighted-average exercise price of options outstanding at end of period	88.71
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average exercise price of options outstanding at beginning of period	371.64
Weighted-average exercise price of options granted	364.59
Weighted-average exercise price of options exercised	279.9
Weighted average exercise price of options canceled	364.59
Weighted-average exercise price of options outstanding at end of period	$ 371.64

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Unvested Roll Forward (Detail) - Restricted Stock Units (RSUs) [Member] shares in Thousands	9 Months Ended
	Oct. 01, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested Beginning balance, Shares | shares	245
Shares, Granted | shares	98
Shares, Vested | shares	(76)
Shares, Forfeited | shares	(23)
Unvested Ending balance, Shares | shares	244
Weighted-average grant date fair value per share of shares unvested at beginning of period | $ / shares	$ 234.97
Weighted-average grant date fair value per share of shares granted | $ / shares	322.99
Weighted-average grant date fair value per share of shares vested | $ / shares	219.3
Weighted-average grant date fair value of shares forfeited | $ / shares	256.22
Weighted-average grant date fair value per share of shares unvested at end of period | $ / shares	$ 273.2

Stock-Based Compensation - Re_2

Stock-Based Compensation - Relevant Data Used to Determine the Value of Performance Shares (Detail) - Performance Stock Unit Plan [Member] - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Performance Stock Units Issued and Significant Assumptions Used to Estimate Fair Values
Shares granted	40	41
Fair value assumptions, risk free interest rate	1.60%	0.20%
Fair value assumptions, expected life in years	2 years 10 months 24 days	2 years 10 months 24 days
Fair value assumptions, expected volatility	25.40%	38.70%
Fair value assumptions, expected volatility of peer companies	34.50%	34.70%
Fair value assumptions, correlation coefficient	43%	45.80%
Fair value assumptions, expected dividends	$ 0

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units Unvested Roll Forward (Detail) - Performance Stock Unit Plan [Member] - $ / shares shares in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Beginning balance, Shares	87
Shares Granted	40	41
Shares Vested	(24)
Shares Forfeited	8
Unvested Ending balance, Shares	111
Weighted-average grant date fair value per share of shares unvested at beginning of period	$ 285.73
Weighted-average grant date fair value per share of shares granted	313.21
Weighted-average grant date fair value per share of shares vested	308.71
Weighted-average grant date fair value per share of shares forfeited	381.32
Weighted-average grant date fair value per share of shares unvested at end of period	$ 297.55

Earnings Per Share - Earnings P

Earnings Per Share - Earnings Per Share Reconciliation (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Earnings Per Share [Abstract]
Net income per basic common share, Net Income (Numerator)	$ 155,998	$ 161,185	$ 480,693	$ 476,604
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities, Net Income (Numerator)	0		0
Net income per diluted common share, Net Income (Numerator)	$ 155,998	$ 161,185	$ 480,693	$ 476,604
Net income per basic common share, Weighted-Average Shares (Denominator)	59,801	61,359	60,200	61,771
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities, Weighted-Average Shares (Denominator)	280	529	321	473
Net income per diluted common share, Weighted-Average Shares (Denominator)	60,081	61,888	60,521	62,244
Net income per basic common share, Per Share Amount	$ 2.61	$ 2.63	$ 7.98	$ 7.72
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities, Per Share Amount	(0.01)	(0.03)	(0.04)	(0.06)
Net income per diluted common share, Per Share Amount	$ 2.6	$ 2.6	$ 7.94	$ 7.66

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	1	1	1	1

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 392,124	$ 268,273	$ 367,554	$ 232,144
Other comprehensive (loss) income, net of tax	(23,001)	(4,435)	(52,525)	2,329
Ending balance	385,236	295,222	385,236	295,222
Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			(99,985)
Other comprehensive (loss) income, net of tax			(54,255)
Ending balance	(154,240)		(154,240)
Unrealized Gain (Loss) on Retirement Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			(11,860)
Other comprehensive (loss) income, net of tax			1,710
Ending balance	(10,150)		(10,150)
Unrealized Gain (Loss) on Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			(20)
Other comprehensive (loss) income, net of tax			20
Ending balance	0		0
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(141,389)	(111,179)	(111,865)	(117,943)
Other comprehensive (loss) income, net of tax			(52,525)
Ending balance	$ (164,390)	$ (115,614)	$ (164,390)	$ (115,614)

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) $ in Millions	Oct. 01, 2022 USD ($)
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated future employer contributions in current fiscal year	$ 3
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated future employer contributions in current fiscal year	$ 6

Retirement Plans - Defined Bene

Retirement Plans - Defined Benefit Plan, Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
United States [Member] | Retiree Healthcare Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 226	$ 198	$ 678	$ 663
Interest cost	145	141	436	419
Expected return on plan assets	(269)	(248)	(807)	(758)
Net amortization: Prior service (credit) cost	(4)	(5)	(14)	(14)
Net amortization: Net actuarial loss		8		8
Net periodic pension cost	98	94	293	318
Non-U.S. Pension Plans [Member] | Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	972	1,140	3,057	3,447
Interest cost	327	309	1,034	936
Expected return on plan assets	(475)	(459)	(1,505)	(1,389)
Settlement loss	139	102	139	102
Net amortization: Prior service (credit) cost	(31)	13	(100)	(67)
Net amortization: Net actuarial loss	150	130	476	653
Net periodic pension cost	$ 1,082	$ 1,235	$ 3,101	$ 3,682

Business Segment Information -

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Oct. 01, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	2
Number of reportable segments	1

Business Segment Information _2

Business Segment Information - Summary of Net Sales for Company's Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation of Revenue [Line Items]
Total net sales	$ 708,555	$ 659,233	$ 2,113,446	$ 1,949,425
Waters Instrument Systems [Member]
Disaggregation of Revenue [Line Items]
Total net sales	274,869	240,475	825,677	717,910
Chemistry Consumables [Member]
Disaggregation of Revenue [Line Items]
Total net sales	128,096	123,045	385,661	368,478
TA Instrument Systems [Member]
Disaggregation of Revenue [Line Items]
Total net sales	61,958	55,613	174,055	155,722
Total product sales [Member]
Disaggregation of Revenue [Line Items]
Total net sales	464,923	419,133	1,385,393	1,242,110
Waters Service [Member]
Disaggregation of Revenue [Line Items]
Total net sales	220,436	218,291	660,371	644,625
TA Service [Member]
Disaggregation of Revenue [Line Items]
Total net sales	23,196	21,809	67,682	62,690
Total service sales [Member]
Disaggregation of Revenue [Line Items]
Total net sales	$ 243,632	$ 240,100	$ 728,053	$ 707,315

Business Segment Information _3

Business Segment Information - Summary of Geographic Sales Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation of Revenue [Line Items]
Total net sales	$ 708,555	$ 659,233	$ 2,113,446	$ 1,949,425
China [Member]
Disaggregation of Revenue [Line Items]
Total net sales	140,080	115,886	399,852	346,030
Japan [Member]
Disaggregation of Revenue [Line Items]
Total net sales	37,095	44,293	123,222	139,702
Asia Other [Member]
Disaggregation of Revenue [Line Items]
Total net sales	102,759	94,423	289,204	268,359
Total Asia [Member]
Disaggregation of Revenue [Line Items]
Total net sales	279,934	254,602	812,278	754,091
United States [Member]
Disaggregation of Revenue [Line Items]
Total net sales	216,380	194,776	638,908	544,124
Americas Other [Member]
Disaggregation of Revenue [Line Items]
Total net sales	40,029	36,225	123,609	109,128
Total Americas [Member]
Disaggregation of Revenue [Line Items]
Total net sales	256,409	231,001	762,517	653,252
Europe [Member]
Disaggregation of Revenue [Line Items]
Total net sales	$ 172,212	$ 173,630	$ 538,651	$ 542,082

Business Segment Information _4

Business Segment Information - Summary of Net Sales by Customer Class (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Revenue, Major Customer [Line Items]
Total net sales	$ 708,555	$ 659,233	$ 2,113,446	$ 1,949,425
Pharmaceutical [Member]
Revenue, Major Customer [Line Items]
Total net sales	405,959	398,338	1,258,902	1,175,191
Industrial [Member]
Revenue, Major Customer [Line Items]
Total net sales	223,968	196,032	641,882	581,884
Academic and government [Member]
Revenue, Major Customer [Line Items]
Total net sales	$ 78,628	$ 64,863	$ 212,662	$ 192,350

Business Segment Information _5

Business Segment Information - Summary of Net Sales of Company Recognized at a Point in Time Versus Over Time (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation of Revenue [Line Items]
Total net sales	$ 708,555	$ 659,233	$ 2,113,446	$ 1,949,425
Chemistry Consumables [Member]
Disaggregation of Revenue [Line Items]
Total net sales	128,096	123,045	385,661	368,478
Service [Member]
Disaggregation of Revenue [Line Items]
Total net sales	243,632	240,100	728,053	707,315
Net Sales Recognized at a Point in Time: [Member]
Disaggregation of Revenue [Line Items]
Total net sales	554,647	504,226	1,652,467	1,495,322
Net Sales Recognized at a Point in Time: [Member] | Instrument Systems [Member]
Disaggregation of Revenue [Line Items]
Total net sales	336,827	296,088	999,732	873,632
Net Sales Recognized at a Point in Time: [Member] | Chemistry Consumables [Member]
Disaggregation of Revenue [Line Items]
Total net sales	128,096	123,045	385,661	368,478
Net Sales Recognized at a Point in Time: [Member] | Service [Member]
Disaggregation of Revenue [Line Items]
Total net sales	89,724	85,093	267,074	253,212
Net Sales Recognized Over Time: [Member]
Disaggregation of Revenue [Line Items]
Total net sales	708,555	659,233	2,113,446	1,949,425
Net Sales Recognized Over Time: [Member] | Service [Member]
Disaggregation of Revenue [Line Items]
Total net sales	$ 153,908	$ 155,007	$ 460,979	$ 454,103